{
  "omopTable": "Episode",
  "origin": "SACT",
  "omopColumns": [
    {
      "name": "nhs_number",
      "operation_description": "Value copied from `NHS_Number`",
      "dataSource": [
        {
          "name": "NHS_Number",
          "description": "Patient NHS Number",
          "origins": [
            {
              "origin": "NHS NUMBER",
              "url": "https://www.datadictionary.nhs.uk/data_elements/nhs_number.html"
            }
          ]
        }
      ],
      "query": "\nselect \n\tdistinct\n\t    NHS_Number,\n\t    Start_Date_Of_Regimen,\n\t    Regimen,\nfrom omop_staging.sact_staging\n\t",
      "lookup_table_markdown": null
    },
    {
      "name": "episode_concept_id",
      "operation_description": "Constant value set to `32531`. Treatment Regimen",
      "dataSource": null,
      "query": null,
      "lookup_table_markdown": null
    },
    {
      "name": "episode_start_date",
      "operation_description": "Converts text to dates.",
      "dataSource": [
        {
          "name": "Start_Date_Of_Regimen",
          "description": "Regimen StartDate",
          "origins": []
        }
      ],
      "query": "\nselect \n\tdistinct\n\t    NHS_Number,\n\t    Start_Date_Of_Regimen,\n\t    Regimen,\nfrom omop_staging.sact_staging\n\t",
      "lookup_table_markdown": null
    },
    {
      "name": "episode_source_value",
      "operation_description": "Value copied from `Regimen`",
      "dataSource": [
        {
          "name": "Regimen",
          "description": "Cancer treatment regimen",
          "origins": []
        }
      ],
      "query": "\nselect \n\tdistinct\n\t    NHS_Number,\n\t    Start_Date_Of_Regimen,\n\t    Regimen,\nfrom omop_staging.sact_staging\n\t",
      "lookup_table_markdown": null
    },
    {
      "name": "episode_type_concept_id",
      "operation_description": "Constant value set to `32818`. EHR Administration record",
      "dataSource": null,
      "query": null,
      "lookup_table_markdown": null
    },
    {
      "name": "episode_object_concept_id",
      "operation_description": "Lookup Cancer treatment regimens concept.",
      "dataSource": [
        {
          "name": "Regimen",
          "description": "Cancer treatment regimen",
          "origins": []
        }
      ],
      "query": "\nselect \n\tdistinct\n\t    NHS_Number,\n\t    Start_Date_Of_Regimen,\n\t    Regimen,\nfrom omop_staging.sact_staging\n\t",
      "lookup_table_markdown": "\r\n\r\n|Regimen|episode_object_concept_id|notes|\r\n|------|-----|-----|\r\n|BEAM|35803616|BEAM|\r\n|CAV|35806944|CAV|\r\n|ChlVPP|35805822|ChlVPP|\r\n|ICE|35805126|ICE|\r\n|PCV|35803682|PCV|\r\n|PEI|912256|PEI|\r\n|R-CODOX-M / R-IVAC|35804381|R-CODOX-M/R-IVAC|\r\n|R-CP|35806665|R-CP|\r\n|R-DHAOx|35805057|R-DHAOx|\r\n|R-GCVP|35805041|R-GCVP|\r\n|MACE|37557218|MACE|\r\n|MMM|1524957|MMM|\r\n|FLAG-IDA|35803457|FLAG-Ida|\r\n|FLAG|35803501|FLAG|\r\n|MATRix|35804413|MATRix|\r\n|VCP|35806343|VCP|\r\n|VDC/IE|35805450|VDC/IE|\r\n|TIP|35806625|TIP|\r\n|ATRA / Arsenic Trioxide|35803549|Arsenic trioxide and ATRA|\r\n|ATRA Arsenic trioxide|35803549|Arsenic trioxide and ATRA|\r\n|Everolimus Lenvatinib|35806906|Everolimus and Lenvatinib|\r\n|Docetaxel Nintedanib|42542355|Docetaxel and Nintedanib|\r\n|Idelalisib Rituximab|35804590|Idelalisib and Rituximab|\r\n|Olaparib Bevacizumab|912013|Olaparib and Bevacizumab|\r\n|Temozolomide Capecitabine|35806577|Capecitabine and Temozolomide|\r\n|Nintedanib Docetaxel|42542355|Docetaxel and Nintedanib|\r\n|Temozolomide Irinotecan|35805455|Irinotecan and Temozolomide|\r\n|Abemaciclib Fulvestrant|35804294|Abemaciclib and Fulvestrant|\r\n|Alpelisib Fulvestrant|35101866|Alpelisib and Fulvestrant|\r\n|Encorafenib Binimetinib|35806137|Binimetinib and Encorafenib|\r\n|Pemetrexed Cisplatin|35806173|Cisplatin and Pemetrexed|\r\n|Dacarbazine Gemcitabine|35806969|Dacarbazine and Gemcitabine|\r\n|Avelumab Axitinib|35806900|Axitinib and Avelumab|\r\n|Ipilimumab Nivolumab|35806133|Ipilimumab-Nivolumab|\r\n|Irinotecan Temozolomide|35805455|Irinotecan and Temozolomide|\r\n|Docetaxel Prednisolone|35102022|Docetaxel and Prednisolone|\r\n|Venetoclax Azacitidine|35803466|Azacitidine and Venetoclax|\r\n|Atezolizumab Bevacizumab|35806408|Atezolizumab and Bevacizumab|\r\n|Ibrutinib Venetoclax|35806097|Ibrutinib and Venetoclax|\r\n|Melphalan +/- Prednisolone|35806351|Melphalan and Methylprednisolone|\r\n|Cyclophosphamide Prednisolone|35803428|Cyclophosphamide and Prednisolone|\r\n|Ifosfamide Doxorubicin|35806965|Doxorubicin and Ifosfamide|\r\n|Obinutuzumab Bendamustine|35804585|Bendamustine and Obinutuzumab|\r\n|Cyclophosphamide Etoposide|35806476|Cyclophosphamide and Etoposide|\r\n|Cetuximab Encorafenib|911998|Encorafenib and Cetuximab|\r\n|Obinutuzumab Venetoclax|35100084|Venetoclax and Obinutuzumab|\r\n|Gemcitabine Docetaxel|35803577|Docetaxel and Gemcitabine|\r\n|Ramucirumab Paclitaxel|35805371|Paclitaxel and Ramucirumab|\r\n|Brentuximab vedotin|35803702|Brentuximab vedotin monotherapy|\r\n|Trifluridine-Tipiracil|35804789|Trifluridine and tipiracil monotherapy|\r\n|Pomalidomide Dexamethasone|42542407|Pomalidomide and Dexamethasone (Pd)|\r\n|Dabrafenib Trametinib|35804100|Dabrafenib and Trametinib|\r\n|Vinblastine Methotrexate|1525155|Methotrexate and Vinblastine|\r\n|Mitomycin Capecitabine + RT|35803671|Capecitabine, Mitomycin, RT|\r\n|Ribociclib Fulvestrant|35804285|Fulvestrant and Ribociclib|\r\n|Mitomycin Capecitabine|35804560|Capecitabine and Mitomycin|\r\n|Tucatinib Capecitabine Trastuzumab|911925|Capecitabine and Trastuzumab (XH) and Tucatinib|\r\n|Venetoclax Rituximab|35804605|Venetoclax and Rituximab|\r\n|Cisplatin Capecitabine + RT|35805336|Capecitabine, Cisplatin, RT|\r\n|Palbociclib Fulvestrant|35804297|Fulvestrant and Palbociclib|\r\n|Carfilzomib Dexamethasone|35806309|Carfilzomib and Dexamethasone (Kd)|\r\n|Sacituzumab govitecan|912024|Sacituzumab govitecan monotherapy|\r\n|Plerixafor + G-CSF Priming|35101641|Plerixafor and G-CSF|\r\n|Ifosfamide Etoposide and HD Methotrexate|35805125|Etoposide, Ifosfamide, Methotrexate|\r\n|Bevacizumab Irinotecan|35803693|Irinotecan and Bevacizumab|\r\n|Pomalidomide + low dose Dexamethasone|42542407|Pomalidomide and Dexamethasone (Pd)|\r\n|Paclitaxel weekly|35804205|Paclitaxel monotherapy, weekly|\r\n|Paclitaxel (90) weekly|35804205|Paclitaxel monotherapy, weekly|\r\n|Temozolomide with concurrent RT|35803687|Temozolomide and RT, then Temozolomide|\r\n|Melphalan intermediate dose with Dexamethasone|905703|Melphalan and Dexamethasone|\r\n|Ipilimumab Nivolumab (melanoma)|35806133|Ipilimumab-Nivolumab|\r\n|EC Docetaxel|1525058|EC-TL (Docetaxel)|\r\n|FEC (100)|35804212|FEC|\r\n|Docetaxel Cyclophosphamide|35804232|Cyclophosphamide and Docetaxel (TC)|\r\n|Capecitabine (5 day) with RT|35806890|Capecitabine and RT|\r\n|Paclitaxel albumin-bound|35804167|Paclitaxel, nanoparticle albumin-bound monotherapy|\r\n|Cyclophosphamide po daily +/- Prednisolone|35803428|Cyclophosphamide and Prednisolone|\r\n|Panobinostat Bortezomib Dexamethasone (PanBorDex)|35806306|Bortezomib and Dexamethasone (Vd) and Panobinostat|\r\n|CHOEP-21 bolus|35803698|CHOEP-21|\r\n|R-ESHAP (daypatient)|35805061|R-ESHAP|\r\n|R-mini CHOP|35805028|R-CHOP|\r\n|Gemcitabine Capecitabine|35804557|Capecitabine and Gemcitabine|\r\n|Cisplatin Etoposide|35805329|Cisplatin and Etoposide (EP)|\r\n|EC Docetaxel Trastuzumab|37560133|EC-TH (Docetaxel) (trastuzumab-dttb)|\r\n|CAV (SCLC)|35806944|CAV|\r\n|Nivolumab Brentuximab vedotin (compassionate use)|35805828|Brentuximab vedotin and Nivolumab|\r\n|Paclitaxel weekly (relapsed/metastatic)|35804205|Paclitaxel monotherapy, weekly|\r\n|R-ESHAP (inpatient)|35805061|R-ESHAP|\r\n|Temozolomide with concurrent RT (support)|35803687|Temozolomide and RT, then Temozolomide|\r\n|Lenalidomide Dexamethasone|35806053|Lenalidomide and Dexamethasone (Rd)|\r\n|Azacitidine|35803465|Azacitidine monotherapy|\r\n|FOLFIRINOX (adjuvant)|35804771|FOLFIRINOX|\r\n|Paclitaxel (weekly for 3 weeks then 1 week off)|35804205|Paclitaxel monotherapy, weekly|\r\n|Vinorelbine (IV) Carboplatin (CrCl)|35806405|Carboplatin and Vinorelbine|\r\n|Cyclophosphamide po weekly +/- Prednisolone|35803428|Cyclophosphamide and Prednisolone|\r\n|Brentuximab vedotin (compassionate use)|35805828|Brentuximab vedotin and Nivolumab|\r\n|R-ICE modified|35805063|R-ICE|\r\n|Paclitaxel weekly (sarcoma)|35804205|Paclitaxel monotherapy, weekly|\r\n|Obinutuzumab Chlorambucil|35804572|Chlorambucil and Obinutuzumab (GClb)|\r\n|Gemcitabine with RT (bladder)|35804152|Gemcitabine and RT|\r\n|Avelumab|35804159|Avelumab monotherapy|\r\n|Trastuzumab Cisplatin Capecitabine|35805363|Capecitabine and Cisplatin (CX) and Trastuzumab|\r\n|Rituximab Gemcitabine Oxaliplatin (R-GemOx)|37559706|R-GemOx (rituximab-rixa)|\r\n|Irinotecan Temozolomide Vincristine|35805455|Irinotecan and Temozolomide|\r\n|Cyclophosphamide TBI (Allograft)|35803613|Cyclophosphamide and TBI|\r\n|FEC (100) Docetaxel (100)|1525108|FEC-TH (Docetaxel)|\r\n|Vinorelbine (oral) Carboplatin (CrCl)|35806405|Carboplatin and Vinorelbine|\r\n|Vinorelbine (oral) Trastuzumab|35804242|Vinorelbine and Trastuzumab (VH)|\r\n|Apixaban|35807094|Apixaban monotherapy|\r\n|Talimogene laherparepvec|35806121|Talimogene laherparepvec monotherapy|\r\n|Everolimus|35805075|Everolimus monotherapy|\r\n|Melphalan PO +/- Prednisolone|35806351|Melphalan and Methylprednisolone|\r\n|Capecitabine with concurrent RT|35806890|Capecitabine and RT|\r\n|Venetoclax Azacitidine (unsuitable for intensive treatment)|35803466|Azacitidine and Venetoclax|\r\n|Encorafenib Binimetinib (compassionate use)|35806137|Binimetinib and Encorafenib|\r\n|Cisplatin Fluorouracil (CF100)|35803676|Cisplatin and Fluorouracil (CF)|\r\n|Paclitaxel albumin-bound Trastuzumab|35804167|Paclitaxel, nanoparticle albumin-bound monotherapy|\r\n|VDTPACE|35806327|DTPACE|\r\n|Pomalidomide Dexamethasone (compassionate use)|42542407|Pomalidomide and Dexamethasone (Pd)|\r\n|Vinorelbine (oral) Carboplatin (EDTA)|35806398|Carboplatin, Vinorelbine, RT|\r\n|Paclitaxel weekly for 3 weeks then 1 week off|35804205|Paclitaxel monotherapy, weekly|\r\n|STELLAR Acalabrutinib monotherapy (Trial)|35804606|Acalabrutinib monotherapy|\r\n|R-CHOP-14 bolus|35805031|R-CHOP-14|\r\n|Temozolomide 75 + RT|35803686|Temozolomide and RT|\r\n|Romidepsin (compassionate use)|35804817|Romidepsin monotherapy|\r\n|Gemcitabine (1250) Cisplatin|35806427|Cisplatin and Gemcitabine/Erlotinib|\r\n|Ipilimumab|35806133|Ipilimumab-Nivolumab|\r\n|Cyclophosphamide Vincristine Dacarbazine (CVD)|35806646|Cyclophosphamide, Dacarbazine, Vincristine|\r\n|Cisplatin Capecitabine with concurrent RT|1525040|Capecitabine and Cisplatin (CX) and RT|\r\n|Capecitabine Trastuzumab|35804312|Capecitabine and Trastuzumab (XH)|\r\n|Busulfan Cyclophosphamide (Allograft)|35806362|Busulfan and Cyclophosphamide, then allo HSCT|\r\n|R-CVP bolus|35805630|R-CVP|\r\n|Lorlatinib|35806425|Lorlatinib monotherapy|\r\n|Panobinostat Bortezomib weekly Dexamethasone (PanBorDex)|35806306|Bortezomib and Dexamethasone (Vd) and Panobinostat|\r\n|Nintedanib|37557063|Nintedanib monotherapy|\r\n|Dasatinib|35804080|Dasatinib monotherapy|\r\n|IMMU-132-13 Sacituzumab govitecan (Trial)|912024|Sacituzumab govitecan monotherapy|\r\n|Axitinib|37560929|Axitinib and Toripalimab|\r\n|Midostaurin (compassionate use)|35803513|Midostaurin monotherapy|\r\n|Capecitabine (5 day) with RT (pancreas)|35806890|Capecitabine and RT|\r\n|BEAM (ambulatory)|35803616|BEAM|\r\n|Dacomitinib|35806428|Dacomitinib monotherapy|\r\n|Dabrafenib Trametinib (metastatic)|35804100|Dabrafenib and Trametinib|\r\n|Fludarabine Melphalan Alemtuzumab (60 late) RIC|35803629|Fludarabine, Melphalan, Alemtuzumab|\r\n|Avelumab Axitinib (EAMS)|35806900|Axitinib and Avelumab|\r\n|Paclitaxel Carboplatin (CrCl) with concurrent RT|35805350|Carboplatin and Paclitaxel (CP) and RT|\r\n|FEC (100) Docetaxel (75) Pertuzumab Trastuzumab (neoadjuvant)|37560136|FEC-THP (Docetaxel) (trastuzumab-dttb)|\r\n|Cisplatin Capecitabine|35805335|Capecitabine and Cisplatin (CX)|\r\n|Temozolomide Irinotecan (TEMIRI)|35805455|Irinotecan and Temozolomide|\r\n|Durvalumab|35804164|Durvalumab monotherapy|\r\n|Cisplatin Fluorouracil (CF80)|35803676|Cisplatin and Fluorouracil (CF)|\r\n|Regorafenib|35804569|Regorafenib monotherapy|\r\n|Ipilimumab Nivolumab (mesothelioma)|35806133|Ipilimumab-Nivolumab|\r\n|rEECur Carboplatin Etoposide (CE) (NCRN Trial)|35806400|Carboplatin and Etoposide (CE)|\r\n|Cisplatin Etoposide with concurrent RT (SCLC)|35805334|Cisplatin, Etoposide, RT|\r\n|Atezolizumab Bevacizumab Paclitaxel Carboplatin (CrCl)|37561589|Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-aveg|\r\n|Carboplatin Pemetrexed (CrCl)|35806172|Carboplatin and Pemetrexed|\r\n|Carboplatin with concurrent RT (CrCl)|35804530|Carboplatin and RT|\r\n|Ruxolitinib|35803508|Ruxolitinib monotherapy|\r\n|Cyclophosphamide oral +/- Methotrexate|35101986|Cyclophosphamide and Methotrexate (CM)|\r\n|Enzalutamide|35804322|Enzalutamide monotherapy|\r\n|Clarithromycin prophylaxis|35806104|Clarithromycin monotherapy|\r\n|Asciminib (compassionate use)|1524898|Asciminib monotherapy|\r\n|Paclitaxel weekly for 3 weeks then 1 week off (sarcoma)|35804205|Paclitaxel monotherapy, weekly|\r\n|Bosutinib|35804082|Bosutinib monotherapy|\r\n|Ceritinib|35804391|Ceritinib monotherapy|\r\n|Gemcitabine (675) Docetaxel (70) (sarcoma)|35803577|Docetaxel and Gemcitabine|\r\n|Pazopanib|37557053|Pazopanib/Everolimus|\r\n|Gilteritinib|35803515|Gilteritinib monotherapy|\r\n|Rucaparib|35806484|Rucaparib monotherapy|\r\n|Inotuzumab ozogamicin cycle 1|35804064|Inotuzumab ozogamicin monotherapy|\r\n|ORACLE Azacitidine (Trial)|35803465|Azacitidine monotherapy|\r\n|Carboplatin Etoposide (EDTA)|35806400|Carboplatin and Etoposide (CE)|\r\n|Lutetium-177 vipivotide tetraxetan (without support medication) (EAMS)|1525150|Lutetium Lu 177 vipivotide tetraxetan monotherapy|\r\n|Mobocertinib|1525157|Mobocertinib monotherapy|\r\n|Cisplatin (100) with concurrent RT|35804144|Cisplatin and RT|\r\n|PRIZM+ Zanubrutinib monotherapy (Trial)|42542412|Zanubrutinib monotherapy|\r\n|FOLFIRINOX (metastatic)|35804771|FOLFIRINOX|\r\n|Vinorelbine (oral) Cisplatin|35804260|Cisplatin and Vinorelbine (CVb)|\r\n|Azacitidine (support)|35803465|Azacitidine monotherapy|\r\n|Paclitaxel weekly premedication (support)|35804205|Paclitaxel monotherapy, weekly|\r\n|Carboplatin Pembrolizumab Pemetrexed (CrCl)|35806403|Carboplatin, Pemetrexed, Pembrolizumab|\r\n|Temozolomide with concurrent RT (patients 65 years and over)|35803687|Temozolomide and RT, then Temozolomide|\r\n|CA059-001 CC-95251 Azacitidine (Trial)|35803465|Azacitidine monotherapy|\r\n|Lanreotide Depot|35806580|Lanreotide Depot/Autogel monotherapy|\r\n|Cisplatin Etoposide with concurrent RT (NSCLC)|37557397|Cisplatin and Etoposide (EP) and RT|\r\n|Cyclophosphamide oral +/- Prednisolone (Sarcoma)|35803428|Cyclophosphamide and Prednisolone|\r\n|FEC (75/500)|35804212|FEC|\r\n|Cisplatin (50) RT|35804144|Cisplatin and RT|\r\n|Niraparib|35806485|Niraparib monotherapy|\r\n|Pemetrexed Carboplatin (CrCl)|35806172|Carboplatin and Pemetrexed|\r\n|Sotorasib|905771|Sotorasib monotherapy|\r\n|Vemurafenib|35804101|Vemurafenib monotherapy|\r\n|ARCADIAN Vinorelbine Cisplatin with RT (Trial)|35805351|Cisplatin, Vinorelbine, RT|\r\n|Fedratinib|35101952|Fedratinib monotherapy|\r\n|MVAC accelerated|35804146|MVAC|\r\n|Gemcitabine|35804135|Gemcitabine monotherapy|\r\n|Cisplatin (50) with concurrent RT|35804144|Cisplatin and RT|\r\n|Abiraterone|35806848|Abiraterone monotherapy|\r\n|CHOP-14 bolus|35803591|CHOP-14|\r\n|Gemcitabine Capecitabine (pancreas)|35804557|Capecitabine and Gemcitabine|\r\n|Mogamulizumab|35804815|Mogamulizumab monotherapy|\r\n|FEC (100) Docetaxel (75) Pertuzumab Trastuzumab IV (adjuvant use only)|37560136|FEC-THP (Docetaxel) (trastuzumab-dttb)|\r\n|Ribociclib (aromatase inhibitor)|35804288|Letrozole and Ribociclib|\r\n|EC Docetaxel Pertuzumab Trastuzumab IV (adjuvant)|37560133|EC-TH (Docetaxel) (trastuzumab-dttb)|\r\n|R-BAC-500|35804616|R-BAC|\r\n|Venetoclax Azacitidine (suitable for standard intensive induction DA)|35803466|Azacitidine and Venetoclax|\r\n|Dalteparin prophylaxis|35807097|Dalteparin monotherapy|\r\n|Midostaurin maintenance|35803513|Midostaurin monotherapy|\r\n|Ivosidenib|35803517|Ivosidenib monotherapy|\r\n|Lomustine|35805719|Lomustine monotherapy|\r\n|Atezolizumab|35804138|Atezolizumab monotherapy|\r\n|Olaparib|35804269|Olaparib monotherapy|\r\n|Liposomal doxorubicin Carboplatin (CrCl)|35805245|Carboplatin and Pegylated liposomal doxorubicin|\r\n|ABVD (3 cycles)|35805802|ABVD|\r\n|Osimertinib|35804394|Osimertinib monotherapy|\r\n|Gemcitabine with concurrent RT (bladder)|35804152|Gemcitabine and RT|\r\n|Asciminib|1524898|Asciminib monotherapy|\r\n|Crizotinib|35806424|Crizotinib monotherapy|\r\n|Daratumumab|35806063|Daratumumab monotherapy|\r\n|Alectinib|35804390|Alectinib monotherapy|\r\n|Glofitamab monotherapy (including Obinutuzumab pre-treatment) (EAMS)|37557451|Glofitamab monotherapy|\r\n|Nilotinib|35804079|Nilotinib monotherapy|\r\n|Fludarabine Melphalan Alemtuzumab (30 late) RIC|35803629|Fludarabine, Melphalan, Alemtuzumab|\r\n|EV-302 Arm A Enfortumab vedotin Pembrolizumab (Trial)|37557435|Enfortumab vedotin and Pembrolizumab|\r\n|Olaparib TABLETS|35804269|Olaparib monotherapy|\r\n|Trastuzumab Cisplatin Capecitabine (GOJ)|35805363|Capecitabine and Cisplatin (CX) and Trastuzumab|\r\n|Inotuzumab ozogamicin cycle 2 onwards achieved CR|35804064|Inotuzumab ozogamicin monotherapy|\r\n|Trametinib|35806139|Trametinib monotherapy|\r\n|AVENuE AVD|35805804|AVD|\r\n|EMA/CO (germ cell)|42542356|EMA/CO|\r\n|Tivozanib|905825|Tivozanib monotherapy|\r\n|Busulfan single dose (oral)|35804638|Busulfan monotherapy|\r\n|MK-6482-013 Belzutifan (MK-6482) 200mg (Trial)|905631|Belzutifan monotherapy|\r\n|Apalutamide (support)|35806850|Apalutamide monotherapy|\r\n|Eribulin (compassionate use)|35804265|Eribulin monotherapy|\r\n|Zoledronic acid 4 weekly|35806301|Zoledronic acid therapy|\r\n|Atezolizumab Carboplatin Etoposide (CrCl)|35806941|Carboplatin and Etoposide (CE) and Atezolizumab|\r\n|Carboplatin Pembrolizumab Pemetrexed without pemetrexed maintenance (CrCl)|35806403|Carboplatin, Pemetrexed, Pembrolizumab|\r\n|M18-803 Ibrutinib Venetoclax (Trial)|35806097|Ibrutinib and Venetoclax|\r\n|Trastuzumab deruxtecan (Enhertu)|42542261|Trastuzumab deruxtecan monotherapy|\r\n|Abemaciclib (aromatase inhibitor)|35804280|Abemaciclib and Anastrozole|\r\n|R-Lenalidomide|35804591|Lenalidomide and Rituximab (R2)|\r\n|Cisplatin Pembrolizumab Pemetrexed daypt|35806412|Cisplatin, Pemetrexed, Pembrolizumab|\r\n|Brigatinib|35806423|Brigatinib monotherapy|\r\n|Trastuzumab emtansine (Kadcyla)|35805230|Trastuzumab emtansine monotherapy|\r\n|MK-6482-013 Belzutifan (MK-6482) 120mg (Trial)|905631|Belzutifan monotherapy|\r\n|Carboplatin Paclitaxel Pembrolizumab (CrCl)|35806415|Carboplatin and Paclitaxel (CP) and Pembrolizumab|\r\n|Cisplatin RT (100 H&N) Daypt|35804144|Cisplatin and RT|\r\n|FOLFIRINOX modified (adjuvant)|35807526|FOLFIRINOX/modified FOLFIRINOX +/- Chemoradiation|\r\n|Cisplatin (40) with concurrent RT (head and neck)|35804144|Cisplatin and RT|\r\n|Abemaciclib (aromatase inhibitor) (metastatic)|35804280|Abemaciclib and Anastrozole|\r\n|Busulfan Fludarabine ATG RIC (Allograft)|35803623|Fludarabine, Busulfan, ATG|\r\n|Durvalumab Gemcitabine Cisplatin (cholangiocarcinoma) (compassionate use)|1524839|Cisplatin and Gemcitabine (GC) and Durvalumab|\r\n|Zoledronic acid 3 weekly|35806301|Zoledronic acid therapy|\r\n|Pembrolizumab Pemetrexed Carboplatin (CrCl)|35806403|Carboplatin, Pemetrexed, Pembrolizumab|\r\n|Cyclophosphamide Fludarabine TBI RIC (Haploidentical)|35803627|Fludarabine, Cyclophosphamide, TBI for dUCB or haploidentical transplant|\r\n|Paclitaxel Carboplatin (EDTA)|35803572|Carboplatin and Paclitaxel (CP)|\r\n|Azacitidine (SC)|35803465|Azacitidine monotherapy|\r\n|Paclitaxel Carboplatin (CrCl)|35803572|Carboplatin and Paclitaxel (CP)|\r\n|Fludarabine Melphalan Alemtuzumab (60) RIC (MUD transplant)|35803629|Fludarabine, Melphalan, Alemtuzumab|\r\n|Trastuzumab emtansine (Kadcyla) (compassionate use)|35805230|Trastuzumab emtansine monotherapy|\r\n|Ifosfamide high dose|35804542|Ifosfamide monotherapy|\r\n|Ruxolitinib support|35803508|Ruxolitinib monotherapy|\r\n|Paclitaxel Carboplatin (CrCl) 7 day with RT|35805350|Carboplatin and Paclitaxel (CP) and RT|\r\n|Cisplatin Etoposide (neuroendocrine)|35805329|Cisplatin and Etoposide (EP)|\r\n|Fedratinib (support)|35101952|Fedratinib monotherapy|\r\n|Pembrolizumab Carboplatin Paclitaxel (CrCl)|35806415|Carboplatin and Paclitaxel (CP) and Pembrolizumab|\r\n|Cladribine (Litak) (SC) Rituximab (hairy cell leukaemia)|35805757|Cladribine and Rituximab|\r\n|Pembrolizumab Pemetrexed Carboplatin without pemetrexed maintenance (CrCl)|35806403|Carboplatin, Pemetrexed, Pembrolizumab|\r\n|CNIS793B12201 Arm 3 Gemcitabine Nab-Paclitaxel (Trial)|35804567|Gemcitabine and nab-Paclitaxel|\r\n|Cisplatin Pemetrexed Daypt|35806173|Cisplatin and Pemetrexed|\r\n|Selpercatinib|912062|Selpercatinib monotherapy|\r\n|Dabrafenib|35804434|Dabrafenib monotherapy|\r\n|Cemiplimab|35804822|Cemiplimab monotherapy|\r\n|Denosumab|35804178|Denosumab monotherapy|\r\n|Carboplatin Etoposide (EDTA) (sarcoma)|35806400|Carboplatin and Etoposide (CE)|\r\n|Chlorambucil (days 1 to 7)|35804622|Chlorambucil monotherapy|\r\n|Bosutinib (compassionate use)|35804082|Bosutinib monotherapy|\r\n|Avapritinib (compassionate use)|42542281|Avapritinib monotherapy|\r\n|Paclitaxel (80) (days 1, 8 and 15)|35804205|Paclitaxel monotherapy, weekly|\r\n|STELLAR CHOP-R (Trial)|35805028|R-CHOP|\r\n|Fludarabine Melphalan Alemtuzumab (90) RIC (MUD transplant)|35803629|Fludarabine, Melphalan, Alemtuzumab|\r\n|Cisplatin Etoposide (oral)|35805329|Cisplatin and Etoposide (EP)|\r\n|DREAMM-3 Pomalidomide Dexamethasone (Trial)|42542407|Pomalidomide and Dexamethasone (Pd)|\r\n|Fludarabine Melphalan Alemtuzumab (60 late) RIC (off study PRO-DLI)|35803629|Fludarabine, Melphalan, Alemtuzumab|\r\n|Zoledronic acid 6 weekly|35806301|Zoledronic acid therapy|\r\n|Polatuzumab Rituximab Cyclophosphamide Doxorubicin Prednisolone (PR-CHP)|37559679|Pola-R-CHP (rituximab-rixa)|\r\n|TOPAZ-1 Durvalumab / placebo monotherapy (Trial)|35804164|Durvalumab monotherapy|\r\n|Lenalidomide (MDS)|35803596|Lenalidomide monotherapy|\r\n|Osimertinib (support)|35804394|Osimertinib monotherapy|\r\n|Atezolizumab Bevacizumab (EAMS)|35806408|Atezolizumab and Bevacizumab|\r\n|Zoledronic acid 4 weekly (support)|35806301|Zoledronic acid therapy|\r\n|Vismodegib (compassionate use)|35804821|Vismodegib monotherapy|\r\n|rEECur Topotecan Cyclophosphamide (off study)|35805453|Cyclophosphamide and Topotecan|\r\n|Vismodegib|35804821|Vismodegib monotherapy|\r\n|Romiplostim|35805922|Romiplostim monotherapy|\r\n|Vinorelbine (oral)|35804241|Vinorelbine monotherapy|\r\n|Cytarabine high dose|35803435|High-dose Cytarabine monotherapy (HiDAC)|\r\n|PARTNER Carboplatin Paclitaxel (Trial)|35803572|Carboplatin and Paclitaxel (CP)|\r\n|Cisplatin (40 weekly) RT (cervix)|35804144|Cisplatin and RT|\r\n|Pacritinib (compassionate use)|1525214|Pacritinib monotherapy|\r\n|Cladribine (Litak) (SC)|35803546|Cladribine monotherapy|\r\n|Carboplatin Fluorouracil (CrCl)|35805773|Carboplatin and Fluorouracil|\r\n|Carboplatin Paclitaxel (NSCLC) (CrCl)|35803572|Carboplatin and Paclitaxel (CP)|\r\n|Niraparib (relapsed)|35806485|Niraparib monotherapy|\r\n|Temozolomide 75 + RT (patients 65 years and over)|35803686|Temozolomide and RT|\r\n|Fluorouracil (96hr CIV) infusor with RT|35804534|Fluorouracil and RT|\r\n|Carboplatin Etoposide (EDTA) (Oral etoposide days 2+3)|35806400|Carboplatin and Etoposide (CE)|\r\n|Busulfan (oral) (single dose) (support)|35804638|Busulfan monotherapy|\r\n|Vinorelbine oral|35804241|Vinorelbine monotherapy|\r\n|Ruxolitinib (compassionate use)|35803508|Ruxolitinib monotherapy|\r\n|VAC (off study)|35806910|VAC|\r\n|Cediranib (compassionate use)|905688|Cediranib monotherapy|\r\n|Capecitabine (1000mg/m2)|35804227|Capecitabine monotherapy|\r\n|MoTD Fludarabine Busulfan experimental group 2 (Trial)|35803612|Busulfan and Fludarabine|\r\n|Mitomycin Capecitabine 42 day|35804560|Capecitabine and Mitomycin|\r\n|DA-EPOCH-R (etopsode phosphate)|35804378|DA-R-EPOCH|\r\n|Pexidartinib (compassionate use)|1524984|Pexidartinib monotherapy|\r\n|Trastuzumab emtansine (Kadcyla) (adjuvant)|35805230|Trastuzumab emtansine monotherapy|\r\n|Liposomal doxorubicin Carboplatin (CrCl) (ovarian)|35805245|Carboplatin and Pegylated liposomal doxorubicin|\r\n|Daratumumab (cycle 1 standard rate then rapid rate subsequent cycles)|35806063|Daratumumab monotherapy|\r\n|Zoledronic acid (lymphoma bone protection) (support)|35806301|Zoledronic acid therapy|\r\n|AVENuE ABVD (Trial)|35805802|ABVD|\r\n|Methylprednisolone 1mg/kg|35807042|Methylprednisolone monotherapy|\r\n|Cisplatin RT (40 H&N) weekly daypt|35804144|Cisplatin and RT|\r\n|Zoledronic acid 3 weekly (support)|35806301|Zoledronic acid therapy|\r\n|Zoledronic acid 6 monthly|35806301|Zoledronic acid therapy|\r\n|DA|35807524|DA 3+10|\r\n|Plerixafor + GCSF priming|35101641|Plerixafor and G-CSF|\r\n|Ipilimumab Nivolumab (mesothelioma) (compassionate use)|35806133|Ipilimumab-Nivolumab|\r\n|Busulfan Fludarabine ATG RIC (AML/MDS) (Allograft)|35803623|Fludarabine, Busulfan, ATG|\r\n|ABVD (ABVD 2 cycles AVD 4 cycles)|35805802|ABVD|\r\n|Dalteparin therapeutic solid tumours|35807097|Dalteparin monotherapy|\r\n|R-Lenalidomide (IV rituximab cycle 1 then SC)|37558891|Lenalidomide and Rituximab-abbs (R2)|\r\n|Cisplatin (40 weekly) RT (cervix) daypt|35804144|Cisplatin and RT|\r\n|Pirtobrutinib (Compassionate Use)|37556847|Pirtobrutinib monotherapy|\r\n|FLAIR Ibrutinib monotherapy (NCRN Trial)|35804581|Ibrutinib monotherapy|\r\n|Ipilimumab Nivolumab (renal cell)|35806133|Ipilimumab-Nivolumab|\r\n|Talazoparib (Compassionate use)|35804270|Talazoparib monotherapy|\r\n|Crizanlizumab (support)|42542402|Crizanlizumab monotherapy|\r\n|Cisplatin (40) with concurrent RT (cervix)|35804144|Cisplatin and RT|\r\n|Dexamethasone daily|35804388|Dexamethasone monotherapy|\r\n|Avelumab (EAMS)|35804159|Avelumab monotherapy|\r\n|Trastuzumab emtansine (Kadcyla) (metastatic)|35805230|Trastuzumab emtansine monotherapy|\r\n|UPSTREAM (EORTC1559) Niraparib (Trial)|35806485|Niraparib monotherapy|\r\n|MoTD Fludarabine Busulfan MF experimental group 2 (Trial)|35803612|Busulfan and Fludarabine|\r\n|Pertuzumab Trastuzumab IV (metastatic)|35804314|Pertuzumab and Trastuzumab|\r\n|Pertuzumab Trastuzumab IV (neoadjuvant)|35804314|Pertuzumab and Trastuzumab|\r\n|Olaparib tablets (Managed access programme)|35804269|Olaparib monotherapy|\r\n|Docetaxel (75) (prostate)|35804162|Docetaxel monotherapy|\r\n|Bevacizumab 15mg/Kg|35803688|Bevacizumab monotherapy|\r\n|Mini-BEAM (5 day) modified|35805837|Mini-BEAM|\r\n|Lenvatinib Pembrolizumab 42 day|42542382|Lenvatinib and Pembrolizumab|\r\n|Venetoclax|35804617|Venetoclax monotherapy|\r\n|ASTX727-02 Decitabine then ASTX727 (Trial)|912034|Decitabine and cedazuridine monotherapy|\r\n|Cyclophosphamide (oral)|35803690|Cyclophosphamide monotherapy|\r\n|Ifosfamide infusional (inpatient)|35804542|Ifosfamide monotherapy|\r\n|STAMPEDE J HT + Abiraterone + Enzalutamide (NCRN Trial)|911935|Abiraterone and Enzalutamide|\r\n|daNIS-3 NIS793 mFOLFOX Bevacizumab (Trial)|37558784|mFOLFOX6-B (bevacizumab-onbe)|\r\n|MaxiCHOP Cytarabine HD Rituximab|37559740|maxi-R-CHOP/R-HiDAC (rituximab-rixa)|\r\n|MoTD Fludarabine Busulfan experimental group 2 (off study)|35803612|Busulfan and Fludarabine|\r\n|XL184-311 Cabozantinib / Placebo (Trial)|35805797|Cabozantinib monotherapy|\r\n|Pertuzumab Trastuzumab IV (adjuvant)|35804314|Pertuzumab and Trastuzumab|\r\n|AZA-MDS-003 (NCRN 525) Azacitidine tablets / placebo (Trial)|35803465|Azacitidine monotherapy|\r\n|Plerixafor + GCSF priming (protocol A)|35101641|Plerixafor and G-CSF|\r\n|Cetuximab Irinotecan Modified DeGramont|35804798|Irinotecan and Cetuximab|\r\n|AZA-MDS-003 (NCRN 525) Azacitidine tablets / placebo (NCRN trial)|35803465|Azacitidine monotherapy|\r\n|Busulfan (oral)|35804638|Busulfan monotherapy|\r\n|Larotrectinib (weeks 1 to 12 only)|35806364|Larotrectinib monotherapy|\r\n|Niraparib (first line maintenance)|35806485|Niraparib monotherapy|\r\n|Irinotecan weekly|35803692|Irinotecan monotherapy|\r\n|Zoledronic acid 6 monthly (support)|35806301|Zoledronic acid therapy|\r\n|PLATO Mitomycin Capecitabine 23 days (ACT3 or ACT4) (NCRN Trial)|35803671|Capecitabine, Mitomycin, RT|\r\n|INTERIM Dabrafenib Trametinib intermittent (Trial)|35804100|Dabrafenib and Trametinib|\r\n|Dexamethasone 40mg 1 day|35804388|Dexamethasone monotherapy|\r\n|Cetuximab Irinotecan Modified de Gramont|35804798|Irinotecan and Cetuximab|\r\n|Bexarotene induction|35804812|Bexarotene monotherapy|\r\n|MoTD Fludarabine Busulfan MF control group 1 (Trial)|35803612|Busulfan and Fludarabine|\r\n|Regorafenib (GIST)|35804569|Regorafenib monotherapy|\r\n|Melphalan high dose (Autograft)|35806058|Melphalan, then auto HSCT|\r\n|Etoposide PO (support)|35803691|Etoposide monotherapy|\r\n|Rituximab single agent (standard)|35803432|Rituximab monotherapy|\r\n|Cetuximab weekly|35804795|Cetuximab monotherapy|\r\n|IMbrave251 (MO42541) Atezolizumab Sorafenib (Trial)|37558188|Sorafenib and Atezolizumab|\r\n|Carboplatin AUC 5 CrCl (support)|35804537|Carboplatin monotherapy|\r\n|ALL-RIC Fludarabine Melphalan Alemtuzumab (MUD) (Trial)|35803629|Fludarabine, Melphalan, Alemtuzumab|\r\n|Etoposide oral flexible dosing (support)|35803691|Etoposide monotherapy|\r\n|Lenvatinib Pembrolizumab 42 day (endometrial)|42542382|Lenvatinib and Pembrolizumab|\r\n|Lenalidomide maintenance (post autologous stem cell transplant)|35803596|Lenalidomide monotherapy|\r\n|Etoposide oral (myeloid)|35803691|Etoposide monotherapy|\r\n|ENRICH Ibrutinib Rituximab (28 day) (NCRN Trial)|35804612|Ibrutinib and Rituximab|\r\n|Vinorelbine (60-80) oral|35804241|Vinorelbine monotherapy|\r\n|213400 (ZEAL-1L) Pembrolizumab Niraparib / placebo (Trial)|37556844|Niraparib and Pembrolizumab|\r\n|Prednisolone reducing dose|35803431|Prednisolone monotherapy|\r\n|Imatinib ALL|35804083|Imatinib monotherapy|\r\n|Rituximab maintenance 1st remission only (2 monthly)|37561187|RT-PEPC; Maintenance (rituximab-rixi)|\r\n|Bortezomib weekly|35804520|Bortezomib monotherapy|\r\n|PETReA Rituximab SC maintenance (Trial)|37561187|RT-PEPC; Maintenance (rituximab-rixi)|\r\n|UKALL 2011 Regimen C Augmented BFM consolidation (off study)|35804055|Augmented BFM consolidation|\r\n|MoTD Fludarabine Melphalan experimental group 2 (Trial)|35803628|Fludarabine and Melphalan|\r\n|Daratumumab (Named patient supply)|35806063|Daratumumab monotherapy|\r\n|Rituximab IV maintenance 1st remission only (2 monthly)|37561187|RT-PEPC; Maintenance (rituximab-rixi)|\r\n|SYD985.002 (TULIP) Lapatinib Capecitabine (Trial)|35804311|Capecitabine and Lapatinib|\r\n|Rituximab Gemcitabine Dexamethasone Cisplatin (R-GDP) (Daypatient)|37559705|R-GDP (rituximab-rixa)|\r\n|Rituximab Gemcitabine Dexamethasone Cisplatin (R-GDP) (daypatient)|37559705|R-GDP (rituximab-rixa)|\r\n|Cetuximab Cisplatin Fluorouracil (100 H&N) infusor|35805359|Cisplatin and Fluorouracil (CF) and Cetuximab|\r\n|Dactinomycin (2 weekly) (germ cell)|35805247|Dactinomycin monotherapy|\r\n|Irinotecan Oxaliplatin Modified DeGramont (FOLFOXIRI)|35807526|FOLFIRINOX/modified FOLFIRINOX +/- Chemoradiation|\r\n|Rituximab SC maintenance 2nd remission only (3 monthly)|37561187|RT-PEPC; Maintenance (rituximab-rixi)|\r\n|Doxorubicin infusion (support)|35804134|Doxorubicin monotherapy|\r\n|Cyclophosphamide IV infusion (support)|35803690|Cyclophosphamide monotherapy|\r\n|Mitotane (Lysodren) (support)|35803585|Mitotane monotherapy|\r\n|Trametinib (compassionate use)|35806139|Trametinib monotherapy|\r\n|Nelarabine (aged 25 years and under) (support)|35806983|Nelarabine monotherapy|\r\n|Epirubicin weekly|35804228|Epirubicin monotherapy|\r\n|Enzalutamide (after at least 3 months of stable dose enzalutamide treatment)|35804322|Enzalutamide monotherapy|\r\n|Pemetrexed maintenance|35804168|Pemetrexed monotherapy|\r\n|CO43805 Mosunetuzumab cycle 1 (Trial)|37557146|Mosunetuzumab monotherapy|\r\n|CABL001A2301 Bosutinib arm (Trial)|35804082|Bosutinib monotherapy|\r\n|AVENuE Avelumab (Trial)|35804159|Avelumab monotherapy|\r\n|Doxycycline (amyloidosis)|35806103|Doxycycline monotherapy|\r\n|DICE Arm 1 Paclitaxel (Trial)|35804166|Paclitaxel monotherapy|\r\n|Paclitaxel Cisplatin (ovarian) daypt|35804527|Cisplatin and Paclitaxel (TP)|\r\n|Bexarotene maintenance|35804812|Bexarotene monotherapy|\r\n|Mitomycin Fluorouracil + RT infusor daypt|35803673|Fluorouracil, Mitomycin, RT|\r\n|Cytarabine HD 3g/m2|35804417|Methotrexate-Cytarabine|\r\n|MoTD Fludarabine Melphalan control group 1 (Trial)|35803628|Fludarabine and Melphalan|\r\n|ENRICH Ibrutinib Rituximab (21 day) (NCRN Trial)|35804612|Ibrutinib and Rituximab|\r\n|Durvalumab 28 day|35804164|Durvalumab monotherapy|\r\n|Fulvestrant intramuscular injection (support)|35804284|Fulvestrant monotherapy|\r\n|Carboplatin AUC 1.5 CrCl (support)|35804537|Carboplatin monotherapy|\r\n|Daratumumab SC (cycles 1 to 6) then IV (cycle 7 onwards) (compassionate use)|35806063|Daratumumab monotherapy|\r\n|Melphalan Prednisolone Thalidomide (MPT)|35806286|MPT|\r\n|Paclitaxel 7 day Carboplatin (CrCl) (ovarian)|35803572|Carboplatin and Paclitaxel (CP)|\r\n|Paclitaxel Carboplatin 21 day (EDTA)|35803572|Carboplatin and Paclitaxel (CP)|\r\n|Radium-223 (Xofigo)|35806862|Radium-223 monotherapy|\r\n|Bevacizumab 7.5mg/kg|35803688|Bevacizumab monotherapy|\r\n|CANC3947 TITAN post trial Apalutamide (off study compassionate use)|35806850|Apalutamide monotherapy|\r\n|Radium 223 (Xofigo)|35806862|Radium-223 monotherapy|\r\n|FEDORA (RG_21-109) Fedratinib pre-treatment (Trial)|35101952|Fedratinib monotherapy|\r\n|Durvalumab 14 day|35804164|Durvalumab monotherapy|\r\n|Osimertinib (adjuvant) (ORBIS)|35804394|Osimertinib monotherapy|\r\n|PATHOS Cisplatin RT (NCRN Trial)|35804144|Cisplatin and RT|\r\n|Blinatumomab 3 days then 4 days (starting on Monday, Tuesday or Friday) <45kg|35804056|Blinatumomab monotherapy|\r\n|Etoposide oral (sarcoma)|35803691|Etoposide monotherapy|\r\n|MoTD Fludarabine Melphalan experimental group 2 (off study)|35803628|Fludarabine and Melphalan|\r\n|ENRICH R-CHOP (NCRN Trial)|35805028|R-CHOP|\r\n|Siltuximab (Castleman disease)|35804521|Siltuximab monotherapy|\r\n|Bevacizumab (compassionate use)|35804319|Bevacizumab-containing therapy|\r\n|ENRICH Ibrutinib Rituximab (28 day) (Trial)|35804612|Ibrutinib and Rituximab|\r\n|Blinatumomab 4 days then 3 days (starting Monday, Thursday or Friday) ambulate|35804056|Blinatumomab monotherapy|\r\n|Phesgo (Pertuzumab with Trastuzumab) SC (adjuvant)|37560284|Pertuzumab and Trastuzumab-herw|\r\n|Vincristine additional (support)|35807043|Vincristine monotherapy|\r\n|Ibrutinib (Waldenstrom?s macroglobulinaemia)|35804581|Ibrutinib monotherapy|\r\n|Bevacizumab Paclitaxel Carboplatin 21 day (CrCl) (cervix)|35806401|Carboplatin and Paclitaxel (CP) and Bevacizumab|\r\n|Obinutuzumab maintenance|35804583|Obinutuzumab monotherapy|\r\n|Blinatumomab 3 days then 4 days (starting Monday, Tuesday or Friday) ambulate|35804056|Blinatumomab monotherapy|\r\n|Blinatumomab 4 days then 3 days (starting on Monday, Thursday or Friday)|35804056|Blinatumomab monotherapy|\r\n|IMMU-132-13 Paclitaxel (Trial)|35804166|Paclitaxel monotherapy|\r\n|TRITON3 CO-338-063 Rucaparib (NCRN Trial)|35806484|Rucaparib monotherapy|\r\n|Larotrectinib (week 13 onwards)|35806364|Larotrectinib monotherapy|\r\n|Blinatumomab 3 days then 4 days (starting on Monday, Tuesday or Friday)|35804056|Blinatumomab monotherapy|\r\n|PRIME-RT Arm B (Trial)|1524906|Arms B (Nelarabine Arms)|\r\n|CLEE011O12301C (NATALEE) Ribociclib arm (Trial)|35804283|Anastrozole, Goserelin, Ribociclib|\r\n|REMoDL-A R-CHOP cycle 1 (Trial)|35805028|R-CHOP|\r\n|FLAIR Ibrutinib Rituximab (NCRN Trial)|35804612|Ibrutinib and Rituximab|\r\n|MVAC accelerated daypt|35804146|MVAC|\r\n|BP42675 Obinutuzumab pre-treatment (Trial)|35804583|Obinutuzumab monotherapy|\r\n|FEDR-MF-002 (FREEDOM 2) Fedratinib (Trial)|35101952|Fedratinib monotherapy|\r\n|EZ|37560722|E-X|\r\n|Abemaciclib (endocrine therapy) (adjuvant)|35804281|Abemaciclib and Letrozole|\r\n|Methotrexate high dose Cytarabine high dose (primary CNS lymphoma)|35804417|Methotrexate-Cytarabine|\r\n|rEECur Ifosfamide (off study)|35804542|Ifosfamide monotherapy|\r\n|CHOP-21 bolus|35805093|CHOP-BCG|\r\n|Rituximab single agent (weekly) (support)|35803432|Rituximab monotherapy|\r\n|GCSF filgrastim priming 0.5MU/Kg/day|37558834|COG AAML1421 protocol (filgrastim-aafi)|\r\n|NEPTUNES Ipilimumab Nivolumab (cohort 2) (Trial)|35806134|Nivolumab-Ipilimumab|\r\n|INITIUM (UV1-202) Ipilimumab Nivolumab (Trial)|35804435|Ipilimumab and Nivolumab|\r\n|MAGNETISMM-5 (C1071005) Arm A Elranatamab (Trial)|37557432|Elranatamab monotherapy|\r\n|Bevacizumab 7.5mg/kg 3 weekly (support)|35803688|Bevacizumab monotherapy|\r\n|Bevacizumab maintenance|35803688|Bevacizumab monotherapy|\r\n|GCSF filgrastim priming 1.0MU/Kg/day|37558834|COG AAML1421 protocol (filgrastim-aafi)|\r\n|Atezolizumab 28 day|35804138|Atezolizumab monotherapy|\r\n|Acalabrutinib (CLL) (compassionate use)|35804606|Acalabrutinib monotherapy|\r\n|OASIS II Arm A Ibrutinib Rituximab (Trial)|35804612|Ibrutinib and Rituximab|\r\n|54767414MMY3003 (NCRN 2993) Daratumumab monotherapy (NCRN Trial)|35806063|Daratumumab monotherapy|\r\n|Atezolizumab 21 day|35804138|Atezolizumab monotherapy|\r\n|Panitumumab Irinotecan Modified de Gramont|35804800|Panitumumab monotherapy|\r\n|UKALL 60+ Arm C Phase 1 Induction (Off Study)|37561927|No induction therapy|\r\n|Intrathecal Cytarabine|35803502|Cytarabine and Thioguanine|\r\n|Carboplatin AUC 5 EDTA (support)|37558432|Carboplatin, Pemetrexed, Bevacizumab-awwb|\r\n|PLATFORM Arm A4 Rucaparib maintenance (NCRN Trial)|35806484|Rucaparib monotherapy|\r\n|Bevacizumab 7.5mg/kg (support)|35804319|Bevacizumab-containing therapy|\r\n|RADAR Arm A ABVD (Trial)|35805802|ABVD|\r\n|Ibrutinib Rituximab (SC) maintenance (Mantle cell lymphoma) 1st line|35804612|Ibrutinib and Rituximab|\r\n|EPIK-B3 (CBYL719H12301) A/B2 Paclitaxel albumin-bound Alpelisib/placebo (Trial)|35804167|Paclitaxel, nanoparticle albumin-bound monotherapy|\r\n|Trastuzumab SC|37561200|TCHP (Docetaxel, SC Trastuzumab)|\r\n|MUK nine b VRD (SC) consolidation part 2 (Trial)|37557464|International ALL Trial consolidation|\r\n|Add Aspirin Randomised trial treatment (NCRN Trial)|35806655|Aspirin monotherapy|\r\n|BREAKWATER (C4221015) Arm C mFOLFOX6 (Trial)|1524843|COG AAML1031 arm A (low-risk)|\r\n|TRIZELL rAd-IFN-MM-301 Celecoxib (Trial)|37557395|Celecoxib, Erlotinib, Methotrexate, Nivolumab|\r\n|RELATIVITY098 (CA224098) BMS-986213 or Nivolumab (Trial)|37557193|Cabozantinib, Ipilimumab, Nivolumab|\r\n|Calcium folinate 350mg|37557474|mFOLFIRINOX (no folinic acid)|\r\n|Denosumab (metastases) 4 weekly (28 day cycle)|35804205|Paclitaxel monotherapy, weekly|\r\n|REMoDL-A R-CHOP cycles 2-6 (Trial)|35806080|R-CHOP/R-DHAP|\r\n|Enzalutamide (metastatic hormone relapsed) (support)|911935|Abiraterone and Enzalutamide|\r\n|Venetoclax continuation (support)|35804617|Venetoclax monotherapy|\r\n|LOXO-BTK-20019 Arm A LOXO-305 (Pirtobrutinib) (Trial)|37556847|Pirtobrutinib monotherapy|\r\n|CEeDD Cohort 3 Cetuximab Irinotecan Modified de Gramont (Trial)|35804798|Irinotecan and Cetuximab|\r\n|Obinutuzumab Glofitamab (compassionate use)|35804583|Obinutuzumab monotherapy|\r\n|Cisplatin Fluorouracil (100 H&N) infusor Daypt|35803672|Cisplatin and Fluorouracil (CF) and RT|\r\n|Carboplatin AUC 6 (CrCl)|37556795|Carboplatin and Doxorubicin|\r\n|ICON 9 Olaparib Arm 2 (Trial)|35804269|Olaparib monotherapy|\r\n|Cisplatin Fluorouracil (80 H&N) infusor Daypt|35803672|Cisplatin and Fluorouracil (CF) and RT|\r\n|Daratumumab SC Bortezomib Dexamethasone (neuropathy) (cycles 1-8 only) (21 day)|35806321|Bortezomib, Thalidomide, Dexamethasone, Panobinostat|\r\n|Cisplatin (50) (cervix)|35102030|Carboplatin and Cisplatin|\r\n|ALL Consolidation cycle 1 (25-60 years)|1525160|No consolidation|\r\n|SYD985.002 (TULIP) SYD985 arm (Trial)|1524843|COG AAML1031 arm A (low-risk)|\r\n|GO40311 BTRC4017A Trastuzumab one step fractionation (Trial)|35804222|Trastuzumab monotherapy|\r\n|Denosumab (metastases)|35804178|Denosumab monotherapy|\r\n|ATRA (Tretinoin) (Emergency use)|35803549|Arsenic trioxide and ATRA|\r\n|D5330C00004 Module 2 Ceralasertib Olaparib (Trial)|912013|Olaparib and Bevacizumab|\r\n|Prednisolone 1mg/kg 7 days|35803431|Prednisolone monotherapy|\r\n|GCSF filgrastim (variable number of days up to 10)|37558834|COG AAML1421 protocol (filgrastim-aafi)|\r\n|Cyclophosphamide IV bolus for use with DTPACE or VTDPACE only (support)|35804235|Dose-dense Cyclophosphamide monotherapy|\r\n|PK 2013 01 VDC/IE (Trial)|35805450|VDC/IE|\r\n|EV-302 Arm B Gemcitabine Cisplatin (Trial)|35806427|Cisplatin and Gemcitabine/Erlotinib|\r\n|Trastuzumab SC 21 day|35804222|Trastuzumab monotherapy|\r\n|CHARIOT Cisplatin Capecitabine stage A2 or B induction (Trial)|35805336|Capecitabine, Cisplatin, RT|\r\n|Nivolumab 28 day|35803677|Nivolumab monotherapy|\r\n|RP3-301 Nivolumab cohorts 3 and 4 (Trial)|35803677|Nivolumab monotherapy|\r\n|CVP bolus (patients under 70 years)|35804599|CVP|\r\n|CONTRAST BI-1607 Trastuzumab (Trial)|35804222|Trastuzumab monotherapy|\r\n|Etoposide IV split bags support|35803691|Etoposide monotherapy|\r\n|Pembrolizumab 400mg (relapsed/metastatic)|35803678|Pembrolizumab monotherapy|\r\n|SCIB1-002 Nivolumab Ipilimumab SCIB1 (Trial)|35806134|Nivolumab-Ipilimumab|\r\n|AML19 CPX-351 (NCRN Trial)|35803473|CPX-351 monotherapy|\r\n|ALL-RIC Intrathecal Methotrexate (Trial)|35804095|Methotrexate monotherapy|\r\n|Prednisolone 1mg/kg 14 days|35803431|Prednisolone monotherapy|\r\n|BEP 5 day metastatic|35803570|BEP|\r\n|Nivolumab 28 day (compassionate use)|35803677|Nivolumab monotherapy|\r\n|Nivolumab 14 day (compassionate use)|35803677|Nivolumab monotherapy|\r\n|GCSF filgrastim 7 days|37558834|COG AAML1421 protocol (filgrastim-aafi)|\r\n|BEP 3 day metastatic|35803570|BEP|\r\n|GCSF filgrastim priming|37558834|COG AAML1421 protocol (filgrastim-aafi)|\r\n|ENRICH Ibrutinib maintenance (Trial)|35804581|Ibrutinib monotherapy|\r\n|Pembrolizumab 200mg then 400mg (relapsed/metastatic)|35803678|Pembrolizumab monotherapy|\r\n|Pembrolizumab 200mg then 400mg (adjuvant)|35803678|Pembrolizumab monotherapy|\r\n|GCSF filgrastim 3 days|37558834|COG AAML1421 protocol (filgrastim-aafi)|\r\n|Pembrolizumab 2mg/kg (metastatic)|35803678|Pembrolizumab monotherapy|\r\n|GO40311 Trastuzumab cycle 1 day -1 (support) (Trial)|35804222|Trastuzumab monotherapy|\r\n|Trastuzumab (8/6) (adjuvant) 21 day (support)|35804222|Trastuzumab monotherapy|\r\n|Atezolizumab 28 day (adjuvant)|35804138|Atezolizumab monotherapy|\r\n|INITIUM (UV1-202) Nivolumab maintenance (Trial)|35803677|Nivolumab monotherapy|\r\n|Prednisolone 1mg/kg 21 days|35803431|Prednisolone monotherapy|\r\n|GCSF filgrastim 5 days|37558834|COG AAML1421 protocol (filgrastim-aafi)|\r\n|Venetoclax titration continuation (support)|35804617|Venetoclax monotherapy|\r\n|Imatinib 400-600 (GIST/sarcomas)|35804083|Imatinib monotherapy|\r\n|Trastuzumab (8/6) (metastatic) 21 day|35804222|Trastuzumab monotherapy|\r\n|Pembrolizumab 400mg (adjuvant)|35803678|Pembrolizumab monotherapy|\r\n|Add Aspirin Run in (NCRN Trial)|35806655|Aspirin monotherapy|\r\n|MAP (APMM)|35806469|MAP|\r\n|Methotrexate high dose (high grade NHL CNS prophylaxis)|35804095|Methotrexate monotherapy|\r\n|Cardamon maintenance (Carfilzomib) (NCRN Trial)|35806280|Carfilzomib monotherapy|\r\n|CVP bolus (patients over 70 years)|35804599|CVP|\r\n|Euro Ewing 2012 VDC/IE (off study)|35805450|VDC/IE|\r\n|Pembrolizumab 21 day then 42 day (adjuvant)|35803678|Pembrolizumab monotherapy|\r\n|CACZ885T2301 Canakinumab/Placebo (Trial)|35803590|Placebo|\r\n|MITHRIDATE (RG_16-148) Pegylated Interferon Alfa-2a (Trial)|35805377|Peginterferon alfa-2a monotherapy|\r\n|54767414MMY3008 (CANC-4387) Daratumumab subequent therarapy (NCRN Trial)|1524917|Dara-Rd (SC daratumumab)|\r\n|Nivolumab 14 day (relapsed/metastatic)|35803677|Nivolumab monotherapy|\r\n|Trastuzumab (8/6) (metastatic) 21 day (support)|35804222|Trastuzumab monotherapy|\r\n|Bevacizumab 14 day (neurofibromatosis 2)|35803688|Bevacizumab monotherapy|\r\n|Cetuximab skin toxicity|35804795|Cetuximab monotherapy|\r\n|ACE-WM-001 ACP-196 (commercial study)|911939|ACP|\r\n|Nivolumab 14 day (adjuvant)|35803677|Nivolumab monotherapy|\r\n|Pembrolizumab 200mg (adjuvant)|35803678|Pembrolizumab monotherapy|\r\n|RP2-001-18 Nivolumab RP2 (Trial)|35803677|Nivolumab monotherapy|\r\n|Pembrolizumab 42 day (adjuvant)|35803678|Pembrolizumab monotherapy|\r\n|Hydroxycarbamide support|35805376|Hydroxyurea monotherapy|\r\n|OptiMATe Arm B MATRIx (Trial)|35804413|MATRix|\r\n|OptiMATe Arm B R-MTX pre-phase (Trial)|37559371|MT-R (rituximab-pvvr)|\r\n|NEPTUNES Nivolumab monotherapy (Trial)|35803677|Nivolumab monotherapy|\r\n|LUD2015-005 Cohort C-FLOT (NCRN Trial)|35805341|FLOT|\r\n|Venetoclax extra doses for cycles delayed after titration completed (support)|35804617|Venetoclax monotherapy|\r\n|Pembrolizumab 42 day (relapsed/metastatic)|35803678|Pembrolizumab monotherapy|\r\n|Nivolumab 28 day (adjuvant)|35803677|Nivolumab monotherapy|\r\n|Nivolumab 14 day (EAMS)|35803677|Nivolumab monotherapy|\r\n|Nivolumab 28 day (metastatic)|35803677|Nivolumab monotherapy|\r\n|OptiMATe Arm A MATRIx (Trial)|35804413|MATRix|\r\n|Pembrolizumab 21 day (adjuvant)|35803678|Pembrolizumab monotherapy|\r\n|Bevacizumab 21 day (neurofibromatosis 2)|35803688|Bevacizumab monotherapy|\r\n|Mouth and bowel support|35803468|Best supportive care|\r\n|Ibrutinib (CLL) >3years progression free interval (no comorbidities) cycles 1-3|35804581|Ibrutinib monotherapy|\r\n|BEP 3 day adjuvant|35807017|Accelerated BEP|\r\n|Brightline-1 Doxorubicin (Trial)|35804134|Doxorubicin monotherapy|\r\n|ALL Consolidation cycle 3 days 1-28 (25-60 years)|37557464|International ALL Trial consolidation|\r\n|BEP 3 day adjuvant (BEP 111)|35807017|Accelerated BEP|\r\n|Docetaxel Carboplatin Trastuzumab (TCH)||No mapping|\r\n|Ixazomib Lenalidomide Dexamethasone||No mapping|\r\n|Pertuzumab Trastuzumab Docetaxel||No mapping|\r\n|Carfilzomib Lenalidomide Dexamethasone||No mapping|\r\n|Epirubicin Oxaliplatin Fluorouracil||No mapping|\r\n|Pembrolizumab Paclitaxel albumin-bound||No mapping|\r\n|Paclitaxel weekly Trastuzumab||No mapping|\r\n|Mitomycin Capecitabine with concurrent RT||No mapping|\r\n|Carfilzomib Pomalidomide Dexamethasone||No mapping|\r\n|Gemcitabine Paclitaxel albumin bound||No mapping|\r\n|Bevacizumab (7.5mg/kg) Paclitaxel Carboplatin (CrCl)||No mapping|\r\n|Docetaxel Carboplatin Trastuzumab (TCH) CrCl||No mapping|\r\n|Temozolomide||No mapping|\r\n|Oxaliplatin Raltitrexed||No mapping|\r\n|Afatinib||No mapping|\r\n|Apalutamide||No mapping|\r\n|Letrozole||No mapping|\r\n|Paclitaxel albumin bound (support)||No mapping|\r\n|Atezolizumab Paclitaxel albumin-bound||No mapping|\r\n|Bevacizumab (15mg/kg) Paclitaxel Carboplatin (CrCl)||No mapping|\r\n|Carboplatin Etoposide Ifosfamide (CarboPEI)||No mapping|\r\n|FOLFOXIRI||No mapping|\r\n|Carboplatin Capecitabine + RT (CrCl)||No mapping|\r\n|Vinorelbine PO (60) Carboplatin AUC5 (CrCl)||No mapping|\r\n|Raltitrexed Oxaliplatin||No mapping|\r\n|Docetaxel||No mapping|\r\n|FLAG-IDA Venetoclax||No mapping|\r\n|Dacarbazine (melanoma)||No mapping|\r\n|Exemestane||No mapping|\r\n|Sunitinib||No mapping|\r\n|EC Docetaxel Pertuzumab Trastuzumab (adjuvant)||No mapping|\r\n|EC Paclitaxel (dose dense)||No mapping|\r\n|Vinorelbine PO (60-80) Cisplatin Daypt||No mapping|\r\n|Palbociclib (aromatase inhibitor)||No mapping|\r\n|Liposomal doxorubicin||No mapping|\r\n|Ponatinib||No mapping|\r\n|Paclitaxel (weekly for 3 weeks then 1 week off) Trastuzumab||No mapping|\r\n|Cabozantinib||No mapping|\r\n|Irinotecan||No mapping|\r\n|Dacarbazine (sarcoma)||No mapping|\r\n|Nivolumab Oxaliplatin Capecitabine||No mapping|\r\n|EC||No mapping|\r\n|Pembrolizumab Oxaliplatin Capecitabine||No mapping|\r\n|Gemcitabine Paclitaxel albumin bound (support)||No mapping|\r\n|Oxaliplatin Capecitabine (OX)||No mapping|\r\n|Olaparib (compassionate use)||No mapping|\r\n|PARTNER Olaparib (Trial)||No mapping|\r\n|Eribulin||No mapping|\r\n|Daratumumab Pomalidomide Dexamethasone||No mapping|\r\n|Bortezomib Thalidomide Dexamethasone (VTD) (28 day cycle)||No mapping|\r\n|Cyclophosphamide Lenalidomide Dexamethasone (weekly cyclophosphamide)||No mapping|\r\n|Cisplatin (60) Etoposide (120) (SCLC) Daypt||No mapping|\r\n|Isatuximab Pomalidomide Dexamethasone||No mapping|\r\n|Zanubrutinib||No mapping|\r\n|Olaparib (relapsed/metastatic)||No mapping|\r\n|Methotrexate Mercaptopurine Indometacin||No mapping|\r\n|Carboplatin Vinorelbine oral with concurrent RT (CrCl)||No mapping|\r\n|Ifosfamide (3g) Doxorubicin (30mg) (sarcoma)||No mapping|\r\n|Bortezomib Thalidomide Dexamethasone (VTD) (21 day cycle)||No mapping|\r\n|Paclitaxel (80) Carboplatin (AUC 2) (CrCl) weekly||No mapping|\r\n|Acalabrutinib||No mapping|\r\n|Bevacizumab Pembrolizumab Carboplatin Paclitaxel (CrCl)||No mapping|\r\n|Pertuzumab Trastuzumab Docetaxel (metastatic)||No mapping|\r\n|Ixazomib Lenalidomide Dexamethasone (named patient supply)||No mapping|\r\n|Doxorubicin Cisplatin Cyclophosphamide (CAP)||No mapping|\r\n|Epirubicin Oxaliplatin Capecitabine (EOX)||No mapping|\r\n|Cisplatin (75) Etoposide (100) (SCLC) Daypt||No mapping|\r\n|Quizartinib (compassionate use)||No mapping|\r\n|Omeprazole||No mapping|\r\n|Erlotinib||No mapping|\r\n|IE/VC||No mapping|\r\n|AMM cycles 5-6 MAP (off study)||No mapping|\r\n|CCS1477-02 CCS1477-MB 4 days on 3 days off (Trial)||No mapping|\r\n|75276617ALE1001 JNJ75276617 tablets (Trial)||No mapping|\r\n|FLAMSA-BU >=60 years (off study)||No mapping|\r\n|Ciprofloxacin for prophylaxis||No mapping|\r\n|ACELARATE Acelarin infusion bag (NCRN Trial)||No mapping|\r\n|Lorazepam||No mapping|\r\n|PlasmaMATCH Cohort E (NCRN Trial)||No mapping|\r\n|Pamidronate 30 28 day (support)||No mapping|\r\n|RomiCar (NCRN Trial)||No mapping|\r\n|Oral cryotherapy||No mapping|\r\n|CLARITY (NCRN Trial)||No mapping|\r\n|ST101-101 ST101 expansion (Trial)||No mapping|\r\n|Atropine sulphate||No mapping|\r\n|Metoclopramide 14 day||No mapping|\r\n|PIANO (NCRN Trial)||No mapping|\r\n|RADAR Arm B A2VD (Trial)||No mapping|\r\n|Colestyramine||No mapping|\r\n|RP2-001-18 re-initiation of RP2 (Trial)||No mapping|\r\n|Micafungin||No mapping|\r\n|Fosaprepitant IV||No mapping|\r\n|AIDA||No mapping|\r\n|APMM 2 cycles (MAP) (off study)||No mapping|\r\n|Loperamide||No mapping|\r\n|RP2-001-18 re-initiation of RP2 (support) (Trial)||No mapping|\r\n|LOGIC2; Run in (early phase trial)||No mapping|\r\n|OVM-200-100 OVM-200 (Trial)||No mapping|\r\n|Metoclopramide 28 day||No mapping|\r\n|LATITUDE (NCRN 433) Open label extension phase (NCRN Trial)||No mapping|\r\n|Hydroxycarbamide initiation||No mapping|\r\n|Magnesium support||No mapping|\r\n|MOTION Vimseltinib (Trial)||No mapping|\r\n|ROMAZA cohorts -2, -1, 1 and 2 (NCRN Trial)||No mapping|\r\n|Anaphylaxis treatment||No mapping|\r\n|NX-5948-301 NX-5948 (Trial)||No mapping|\r\n|RPL-001-16 re-initiation (support) (Trial)||No mapping|\r\n|Metoclopramide 7 day||No mapping|\r\n|RXC004/0001 run in (Trial)||No mapping|\r\n|Loratadine||No mapping|\r\n|Cetirizine 28 days||No mapping|\r\n|Cetirizine 7 days||No mapping|\r\n|ATTAINMENT Module 1 MDX-124 (Trial)||No mapping|\r\n|Ondansetron 12 days prn||No mapping|\r\n|Movicol||No mapping|\r\n|KEYNOTE-867 (MK3475-867) (Trial)||No mapping|\r\n|Metoclopramide 3 day||No mapping|\r\n|High emetic risk ondanestron weekly cisplatin||No mapping|\r\n|Pyridoxine 50mg||No mapping|\r\n|Famotidine||No mapping|\r\n|Euro Ewing 2012 IE/VC (off study)||No mapping|\r\n|Aciclovir prophylaxis 200mg tds||No mapping|\r\n|Entecavir||No mapping|\r\n|Hydroxycarbamide||No mapping|\r\n|Nystatin||No mapping|\r\n|Palonosetron IV||No mapping|\r\n|KEYNOTE-867 (MK3475-867-00) (Trial)||No mapping|\r\n|Calcium carbonate Vitamin D||No mapping|\r\n|Ibandronic acid||No mapping|\r\n|Aciclovir-prophylaxis||No mapping|\r\n|Ondansetron metoclopramide 1 day||No mapping|\r\n|Ondansetron metoclopramide||No mapping|\r\n|Furosemide PO 1 day||No mapping|\r\n|Famotidine premed||No mapping|\r\n|Ondansetron metoclopramide days 1, 8 and 15||No mapping|\r\n|ALL Maintenance (25-60 years)||No mapping|\r\n|RP3-301 RP3 (support) (Trial)||No mapping|\r\n|Levofloxacin prophylaxis 28 days||No mapping|\r\n|CEDAR Enadenotucirev loading (Trial)||No mapping|\r\n|Dexrazoxane (cardiotoxicity)||No mapping|\r\n|ANIMATE (CA209-445) (Trial)||No mapping|\r\n|Low emetic risk prochlorperazine||No mapping|\r\n|Sodium chloride 0.9% IV ambulatory infusor||No mapping|\r\n|Epaderm Emollient||No mapping|\r\n|Fluconazole prophylaxis||No mapping|\r\n|Ondansetron metoclopramide 5 days||No mapping|\r\n|PICC line pack||No mapping|\r\n|MUK nine b RD (SC) maintenance (Trial)||No mapping|\r\n|Cyclizine||No mapping|\r\n|COMICE (Trial)||No mapping|\r\n|High emetic rsk ondansetron metoclopramide days 1, 8 and 15||No mapping|\r\n|High emetic risk ondansetron metoclopramide 5 days||No mapping|\r\n|Lorazepam daily||No mapping|\r\n|Olanzapine||No mapping|\r\n|Rasburicase||No mapping|\r\n|Ondansetron day 1 oral premedication||No mapping|\r\n|Moderate emetic risk ondansetron metoclopramide 5 days||No mapping|\r\n|Moderate emetic risk ondansetron 1 day||No mapping|\r\n|Moderate emetic risk ondansetron liquids 1 day||No mapping|\r\n|Moderate emetic risk ondansetron 3.5 days||No mapping|\r\n|Moderate emetic risk ondansetron 5 days||No mapping|\r\n|Darbepoeitin weekly||No mapping|\r\n|Moderate emetic risk ondansetron 1.5 days||No mapping|\r\n|High emetic risk ondansetron 5 days||No mapping|\r\n|High emetic risk ondansetron 2 days||No mapping|\r\n|High emetic risk ondansetron 1.5 days||No mapping|\r\n|High emetic risk ondansetron 1 day||No mapping|\r\n|Moderate emetic risk ondansetron 1 day weekly||No mapping|\r\n|Paracetamol soluble||No mapping|\r\n|Moderate emetic risk ondansetron metoclopramide 1 day||No mapping|\r\n|Moderate emetic risk ondansetron metoclopramide days 1, 8 and 15||No mapping|\r\n|High emetic risk ondansetron 3 days||No mapping|\r\n|Low emetic risk domperidone||No mapping|\r\n|High emetic risk ondansetron metoclopramide 1 day||No mapping|\r\n|Colesevelam||No mapping|\r\n|Moderate emetic risk ondansetron liquids||No mapping|\r\n|High emetic risk ondansetron liquids||No mapping|\r\n|High emetic risk ondansetron days 1, 8 and 15||No mapping|\r\n|AMADEUS (Trial)||No mapping|\r\n|Diprobase||No mapping|\r\n|Mesna IV||No mapping|\r\n|Pembrolizumab 21 day then 42 day (relapsed/metastatic)||No mapping|\r\n|ACCEPT Phase 1 cohort 2 and phase 2 cycles 1-6 (Trial)||No mapping|\r\n|NUTIDE 302 NUFIRI Q1W (Trial)||No mapping|\r\n|Liposomal amphotericin B (Ambisome) prophylaxis||No mapping|\r\n|ONC001 Part A1 cohort 4 (4 weekly) (Trial)||No mapping|\r\n|DREAMM-9 Belantamab mafodontin VRd (every cycle) (Trial)||No mapping|\r\n|UKALL 2011 Regimen B1/C1 maintenance (males) (off study)||No mapping|\r\n|CC-92480-MM-001 21/28 OD schedule (Trial)||No mapping|\r\n|DREAMM-9 Belantamab mafodontin Rd maintenance (every cycle) (Trial)||No mapping|\r\n|Difflam||No mapping|\r\n|RP2-001-18 RP2 (Trial)||No mapping|\r\n|Posaconazole prophylaxis||No mapping|\r\n|Sodium chloride 0.9% IV (Venetoclax hydration)||No mapping|\r\n|Sodium chloride 0.9% 500ml IV infusion||No mapping|\r\n|75276617ALE1001 JNJ75276617 capsules (Trial)||No mapping|\r\n|Ferinject 1000mg IVI||No mapping|\r\n|Paracetamol oral||No mapping|\r\n|Hydroxycarbamide (alternate day dosing)||No mapping|\r\n|Stem cells||No mapping|\r\n|Methylene blue||No mapping|\r\n|TIMEPOINT (MNA-3521-012) MTL-CEBPA Pembrolizumab (Trial)||No mapping|\r\n|CANC3947 TITAN Open label (NCRN Trial)||No mapping|\r\n|TALAPRO-2 (C3441021) part 2 (Trial)||No mapping|\r\n|Pamidronate 30 28 day||No mapping|\r\n|PEACOCC (Trial)||No mapping|\r\n|ARCADIAN Atovaquone (Trial)||No mapping|\r\n|Calcium levofolinate 175mg||No mapping|\r\n|EORTC-HGUS 62113-55115 (Trial)||No mapping|\r\n|IMP-MEL IMM60 (Trial)||No mapping|\r\n|Sodium chloride IV infusion||No mapping|\r\n|WINGMEN Xentuzumab (Trial)||No mapping|\r\n|OCTOVA Arm C (NCRN Trial)||No mapping|\r\n|ALL Intensification / CNS prophylaxis (25-60 years)||No mapping|\r\n|ALL Consolidation cycle 3 days 29-42 (25-60 years)||No mapping|\r\n|1480-0001 (IV STING) BI 1703880 Ezabenlimab (Trial)||No mapping|\r\n|Pembrolizumab 21 day (relapsed/metastatic)||No mapping|\r\n|STP938-101 STP938 (Trial)||No mapping|\r\n|Codeine Phosphate po||No mapping|\r\n|IMG-7289-CTP-102 IMG-7289 (Trial)||No mapping|\r\n|Potassium chloride 20mmol IV||No mapping|\r\n|Rituximab weekly (ITP)||No mapping|\r\n|Lamivudine||No mapping|\r\n|Levomepromazine||No mapping|\r\n|DREAMM-9 Belantamab mafodontin Rd maintenance (every 3rd cycle) (Trial)||No mapping|\r\n|RMS 2005 IVADo cycles 1-3 (off study)||No mapping|\r\n|Chlorphenamine 7 days||No mapping|\r\n|ACE-CL-001 ACP-196 Cohort 2b (NCRN Trial)||No mapping|\r\n|Darbepoeitin 3 weekly||No mapping|\r\n|MOTION Vismeltinib (Trial)||No mapping|\r\n|Azithromycin prophylaxis (250mg) 3 x week 28 day||No mapping|\r\n|Atropine sulphate (5 days)||No mapping|\r\n|Isoniazid||No mapping|\r\n|Ranitidine premed IV||No mapping|\r\n|Azithromycin prophylaxis (250mg) 3 x week 21 day||No mapping|\r\n|Pentamidine prophylaxis IV||No mapping|\r\n|EP 166/50 daypt||No mapping|\r\n|BEP 3 day metastatic (NSCGT) daypt||No mapping|\r\n|Magnesium sulphate 8mmol IV||No mapping|\r\n|75276617ALE1001 JNJ75276617 (Trial)||No mapping|\r\n|M16-191 Transform-1 (Trial)||No mapping|\r\n|DREAMM-9 Belantamab mafodontin VRd (every 3rd cycle from cycle 4) (Trial)||No mapping|\r\n|CCS1477-02 CCS1477 3 days on 4 days off (Trial)||No mapping|\r\n|Cimetidine premed||No mapping|\r\n|CC-92480-MM-001 20/28 schedule (Trial)||No mapping|\r\n|Metoclopramide 21 day||No mapping|\r\n|EORTC-HGUS 62113-55115 (open label) (Trial)||No mapping|\r\n|ACE-CL-001 ACP-196 Cohort 8 (NCRN Trial)||No mapping|\r\n|NUTIDE 302 NUFOX Q1W (Trial)||No mapping|\r\n|RP3-301 RP3 (Trial)||No mapping|\r\n|RATinG Lenzilumab (stage 1) (support) (Trial)||No mapping|\r\n|CA290-841 (CONFIRM) (Trial)||No mapping|\r\n|Magnesium sulphate 20mmol IV||No mapping|\r\n|Ipi-Glio Arm A (Trial)||No mapping|\r\n|Ondansetron for oral Vinorelbine days 1, 8 and 15||No mapping|\r\n|CC-4047-MM-013 (Commercial trial)||No mapping|\r\n|LUD2015-005 Post surgery Cohorts C and D (NCRN Trial)||No mapping|\r\n|BEP 5 day metastatic (NSCGT) daypt||No mapping|\r\n|RMS 2005 IVADo IVA cycles 4-9 (off study)||No mapping|\r\n|Anaphylaxis prophylaxis||No mapping|\r\n|STAMPEDE K SoC & Metformin (NCRN Trial)||No mapping|\r\n|CEeDD SonoTran particles cohorts 1, 2B and 3B (Trial)||No mapping|\r\n|D9571C00001 AZD7789 (Trial)||No mapping|\r\n|Allopurinol for prevention of tumour lysis syndrome||No mapping|\r\n|Aciclovir prophylaxis 200mg bd||No mapping|\r\n|NX-1607-101 NX-1607 (Trial)||No mapping|\r\n|UKALL 2011 Regimen B Standard BFM consolidation (off study)||No mapping|\r\n|UKALL 60+ Arm A Maintenance (off study)||No mapping|\r\n|MATTERHORN (D910GC00001) Durvalumab/placebo FLOT (Trial)||No mapping|\r\n|MATRIX NLMT Arm J (Ceralasertib Durvalumab) (Trial)||No mapping|\r\n|M16-109 (REFINE) Navitoclax monotherapy (Trial)||No mapping|\r\n|Capecitabine (1250) adjuvant||No mapping|\r\n|Rituximab 100mg dose (support)||No mapping|\r\n|MonarchE Arm A Abemaciclib + SoC endocrine (NCRN Trial)||No mapping|\r\n|KY1044-CT01 Atezolizumab KY1044 24mg infusion bag (Trial)||No mapping|\r\n|Dexrazoxane||No mapping|\r\n|STAR-221 Arm A Domvanalimab Zimberelimab FOLFOX (Trial)||No mapping|\r\n|Capecitabine Phesgo SC (metastatic)||No mapping|\r\n|CRUKD/22/002 HMBD-001 Arm 1 monotherapy (Trial)||No mapping|\r\n|Daratumumab SC (c1-3) then IV (c4-8) Bortezomib Dexam (neuropathy 21d) (compas)||No mapping|\r\n|UKALL 60+ Arm D Consolidation 1 (off study)||No mapping|\r\n|VDTPACE (cyclophosphamide bolus)||No mapping|\r\n|AML19 Cytarabine high dose (NCRN Trial)||No mapping|\r\n|GCSF filgrastim||No mapping|\r\n|NG-641-03 (NEBULA) NG-641 Nivolumab (Trial)||No mapping|\r\n|RPL-001-16 Phase 1 expansion or Phase 2 Nivolumab & RP1 (Trial)||No mapping|\r\n|Bendamustine 90-R (NHL)||No mapping|\r\n|ALL Consolidation cycle 2 (25-60 years)||No mapping|\r\n|5F9005 Magrolimab Azacitidine AML/MDS expansion (Trial)||No mapping|\r\n|STAMPEDE G HT + Abiraterone (NCRN Trial)||No mapping|\r\n|Co-trimoxazole 480mg 3xweekly||No mapping|\r\n|D933LC00001 (BEGONIA) Arm 1 (Trial)||No mapping|\r\n|PRIME-RT Arm A (Trial)||No mapping|\r\n|Cisplatin 21 day (ovarian) daypt||No mapping|\r\n|CT7001-001 Module 1 Cycle 1 onwards (Trial)||No mapping|\r\n|Imatinib CML (support)||No mapping|\r\n|ADCT-402-201 (Trial)||No mapping|\r\n|ACE-536-MDS-002 (COMMANDS) Epoetin alfa (Trial)||No mapping|\r\n|ACE-536-MF-001 (Trial)||No mapping|\r\n|KRT-232-101 28 day cycle (Trial)||No mapping|\r\n|MEDI4736-NHL-001 Arm B (NHL) (NCRN Trial)||No mapping|\r\n|D933LC00001 (BEGONIA) Arm 2 (Trial)||No mapping|\r\n|GS-US-546-5920 Cohort 2 Mag+MEC (Trial)||No mapping|\r\n|Aprepitant with dexamethasone (day 1 on ward)||No mapping|\r\n|UKALL 60+ Arm C Maintenance (Off Study)||No mapping|\r\n|PETReA Obintuzumab maintenance (Trial)||No mapping|\r\n|Ibrutinib (CLL) (support)||No mapping|\r\n|ALL Consolidation cycle 4 (25-60 years)||No mapping|\r\n|STAR-221 Arm B Nivolumab FOLFOX (Trial)||No mapping|\r\n|Pembrolizumab 200mg (relapsed/metastatic)||No mapping|\r\n|CA017-078 Nivolumab BMS-986205/Placebo adjuvant (Trial)||No mapping|\r\n|Aprepitant with dexamethasone (day 1 at home)||No mapping|\r\n|D933LC00001 (BEGONIA) Arm 6 (Trial)||No mapping|\r\n|Methotrexate 50 (germ cell)||No mapping|\r\n|Lansoprazole||No mapping|\r\n|RADAR (Myeloma XV) RCyBorD induction (Trial)||No mapping|\r\n|CEDAR Capecitabine RT Enadenotucirev maintenance (Trial)||No mapping|\r\n|PEMBROWM Pembrolizumab Rituximab (Trial)||No mapping|\r\n|ONC001 Part A or Part A1 cohorts 1 and 2 (2 weekly) (Trial)||No mapping|\r\n|RP3-301 RP3 Nivolumab cohorts 1 and 5 (Trial)||No mapping|\r\n|MUK nine b VRDd consolidation part 1 (Trial)||No mapping|\r\n|UKALL 2011 Regimen B3/C3 maintenance (males) (NCRN Trial)||No mapping|\r\n|MITHRIDATE (RG_16-148) Ruxolitinib (Trial)||No mapping|\r\n|Cisplatin hydration (cisplatin dose >=61mg/m2)||No mapping|\r\n|ONC001 Part A1 cohort 3 (3 weekly) (Trial)||No mapping|\r\n|CCS1477-02 CCS1477-MB 4 days on 3 days off bd dosing (without azoles) (Trial)||No mapping|\r\n|ACCEPT Phase 1 cohort 2 and phase 2 cycles 7-8 (Trial)||No mapping|\r\n|D8231C00001 AZD4573 cycle 1 (Trial)||No mapping|\r\n|CC-90009-AML-001 Gen 2 days 1-10 (Trial)||No mapping|\r\n|Ibrutinib (Mantle cell lymphoma) 2nd line||No mapping|\r\n|Atezolizumab 21 day (relapsed/metastatic)||No mapping|\r\n|GCSF pegfilgrastim||No mapping|\r\n|RAMPART Arm C (Trial)||No mapping|\r\n|GS-US-546-5920 Cohort 1 Mag+Ven+Aza (Trial)||No mapping|\r\n|D933LC00001 (BEGONIA) Arm 5 (Trial)||No mapping|\r\n|RMS 2005 Vinorelbine Cyclophosphamide maintenance (Off  Study)||No mapping|\r\n|Fludarabine Melphalan RIC (Allograft)||No mapping|\r\n|Denosumab (metastases) 6 weekly||No mapping|\r\n|Rituximab IV 375mg/m2||No mapping|\r\n|EC Docetaxel Phesgo SC (neoadjuvant node negative / unknown)||No mapping|\r\n|Bendamustine 90-R firstline (CLL)||No mapping|\r\n|Carboplatin desensitisation (CrCl) (support)||No mapping|\r\n|Aprepitant without dexamethasone (day 1 on ward)||No mapping|\r\n|Aspirin 75||No mapping|\r\n|AML19 FLAG-Ida course 2 standard risk (NCRN Trial)||No mapping|\r\n|Nivolumab Oxaliplatin Modified de Gramont (EAMS)||No mapping|\r\n|LOXO-BTK-20022 Arm B Venetoclax Rituximab cycle 1 (Trial)||No mapping|\r\n|Majic Ruxolitinib PV (NCRN Trial)||No mapping|\r\n|TRIZELL rAd-IFN-MM-301 rAd-IFN Celecoxib (Trial)||No mapping|\r\n|Add Aspirin randomised trial treatment (NCRN Trial)||No mapping|\r\n|Doxorubicin (urgent use)||No mapping|\r\n|UKALL 60+ Arm A Consolidation (off study)||No mapping|\r\n|ENHANCE (5F9009) Magrolimab / placebo Azacitidine (Trial)||No mapping|\r\n|Carboplatin desensitisation (CrCl)||No mapping|\r\n|LOXO-BTK-20022 Arm B Venetoclax Rituximab cycles 2-25 (Trial)||No mapping|\r\n|Trastuzumab IV||No mapping|\r\n|Cetuximab Oxaliplatin Modified de Gramont||No mapping|\r\n|ACTICCA-1 Gemcitabine Cisplatin (Trial)||No mapping|\r\n|UKALL 60+ Arm D Phase 1 and 2 Induction (off study)||No mapping|\r\n|Melphalan high dose (Autograft) (renal impairment)||No mapping|\r\n|Carboplatin AUC 5 (EDTA)||No mapping|\r\n|ISIS-702843-CS4 Cohort A (Trial)||No mapping|\r\n|INITIUM (UV1-202) UV1 Ipilimumab Nivolumab (Trial)||No mapping|\r\n|FGCL-4592-082 Roxadustat / placebo (Trial)||No mapping|\r\n|CABL001J12301 Arm 2 Imatinib (Trial)||No mapping|\r\n|Ibrutinib Rituximab (IV cycle 1 then SC c2-6) (Mantle cell lymphoma) 1st line||No mapping|\r\n|PCYC-1128-CA Cohort 5 Ibrutinib (NCRN Trial)||No mapping|\r\n|PROSPER Enzalutamide open label (commercial trial)||No mapping|\r\n|PRISM (ACE-LY-111) Arm 1 Acalabrutinib AZD9150 (Trial)||No mapping|\r\n|R3767-ONC-1613 REGN3767 and REGN2810 combination (Trial)||No mapping|\r\n|1426-0001 Arm B BI 138746 BI 754091 (Trial)||No mapping|\r\n|Intrathecal Methotrexate||No mapping|\r\n|Belantamab mafodontin (GSK2857916) (compassionate use)||No mapping|\r\n|NUTIDE 302 Bevacizumab (support) (Trial)||No mapping|\r\n|RiVa Arm B (Trial)||No mapping|\r\n|Nivolumab 14 day||No mapping|\r\n|NUTIDE 701 NUC-7738 Pembrolizumab (Trial)||No mapping|\r\n|Cisplatin hydration (cisplatin dose =<40mg/m2)||No mapping|\r\n|CA017-078 Gemcitabine Cisplatin Nivolumab BMS-986205/Placebo (Trial)||No mapping|\r\n|FLAIR Fludarabine Cyclophosphamide Rituximab (NCRN Trial)||No mapping|\r\n|Phesgo (Pertuzumab with Trastuzumab) SC (metastatic)||No mapping|\r\n|PRO-DLI (Fludarabine Melphalan Alemtuzumab) (Trial)||No mapping|\r\n|Carboplatin AUC 7 (CrCl)||No mapping|\r\n|Denosumab (metastases) 4 weekly (84 day cycle)||No mapping|\r\n|BEACOPDac escalated||No mapping|\r\n|UKALL 2011 Regimen C Capizzi interim maintenance (off study)||No mapping|\r\n|Docetaxel (100) (adjuvant) 21 day||No mapping|\r\n|Irinotecan Modified DeGramont (NET)||No mapping|\r\n|ATRA (Tretinoin) (emergency use continuation) support||No mapping|\r\n|D8231C00001 AZD4573 cycle 2 onwards (Trial)||No mapping|\r\n|CDK-002-101 (Trial)||No mapping|\r\n|Constellation (0610-02) Arms 2 and 3 CPI-610 Ruxolitinib (Trial)||No mapping|\r\n|CRUKD/11/001;Vandeta+Selumetinib(od)dose escalation_C2onwards (EarlyPhaseTrial)||No mapping|\r\n|Erythropoietin zeta weekly||No mapping|\r\n|Carboplatin 21 day (CrCl) breast||No mapping|\r\n|Imatinib (GIST)||No mapping|\r\n|Nivolumab Oxaliplatin Modified de Gramont||No mapping|\r\n|CO41942 Mosun+Len Mosunetuzumab Lenalidomide cycles 2-12 (Trial)||No mapping|\r\n|CA017-078 Gemcitabine Cisplatin (Trial)||No mapping|\r\n|Cetuximab 2 weekly combination (support)||No mapping|\r\n|ENRICH Ibrutinib additional (NCRN Trial)||No mapping|\r\n|Irinotecan Capecitabine 21 day||No mapping|\r\n|UPSTREAM (EORTC1559) Durvalumab Monalizumab (Trial)||No mapping|\r\n|Dexamethasone pre docetaxel 16mg IV 1 day||No mapping|\r\n|Denosumab (metastases) 4 weekly||No mapping|\r\n|LOXO-BTK-20019 Arm B Ibrutinib (Trial)||No mapping|\r\n|Constellation (0610-02) Arm 4 CPI-0610 monotherapy (Trial)||No mapping|\r\n|CA224048 Relatlimab Nivolumab Ipilimumab (Trial)||No mapping|\r\n|Phesgo (Pertuzumab with Trastuzumab) SC (adjuvant) (support)||No mapping|\r\n|REMoDL-A Acalabrutinib R-CHOP cycles 2-6 (Trial)||No mapping|\r\n|PROMise PLX2853 Ruxolitinib (Trial)||No mapping|\r\n|Dexamethasone pre docetaxel 20mg IV 1 day||No mapping|\r\n|FLA-IDA||No mapping|\r\n|LOXO-BTK-20022 Arm A Pirtobrutinib Venetoclax Rituximab (Trial)||No mapping|\r\n|CNIS793B12301 (dANIS-2) NIS793/placebo Gemcitabine Nab-paclitaxel (Trial)||No mapping|\r\n|5F9003 Hu5F9-G4 + R-GemOx cycle 1 (Trial)||No mapping|\r\n|Ibrutinib (lymphoma) (compassionate use)||No mapping|\r\n|UKALL 2011 Regimen C Delayed intensification (off study)||No mapping|\r\n|CABL001E2201 Imatinib arm (Trial)||No mapping|\r\n|daNIS-3 NIS793 FOLFIRI Bevacizumab (Trial)||No mapping|\r\n|EC Docetaxel Phesgo SC (neoadjuvant node positive)||No mapping|\r\n|Imatinib ALL (support)||No mapping|\r\n|TRIZELL rAd-IFN-MM-301 Gemcitabine (Trial)||No mapping|\r\n|CC-4047-MM-007 (CANC4276) Bortezomib Dexamethasone Pomalidomide (NCRN Trial)||No mapping|\r\n|Carboplatin 21 day (EDTA)||No mapping|\r\n|Daratumumab Bortezomib Dexamethasone (cycle 9 onwards) (28 day) rapid rate||No mapping|\r\n|Dexamethasone pre/post docetaxel 8mg po weekly prostate||No mapping|\r\n|Cyclophosphamide priming prior to PBSC harvest||No mapping|\r\n|Irinotecan Oxaliplatin Modified de Gramont modified (neoadjuvant)||No mapping|\r\n|APHRODITE Capecitabine (Trial)||No mapping|\r\n|FEDORA (RG_21-109) Fedratinib Ropeginterferon alfa-2b (Trial)||No mapping|\r\n|Panitumumab Irinotecan Modified DeGramont||No mapping|\r\n|Irinotecan Modified de Gramont||No mapping|\r\n|Enzalutamide (metastatic hormone relapsed)||No mapping|\r\n|Methotrexate weekly (Large granular cell leukaemia)||No mapping|\r\n|Imatinib 400-600||No mapping|\r\n|STELLAR CHOP-R Acalabrutinib (Trial)||No mapping|\r\n|Carboplatin VTDPACE (support)||No mapping|\r\n|Daratumumab Bortezomib Dexamethasone (neuropathy) (cycles 1 to 8 only) (21 day)||No mapping|\r\n|CO41942 Mosun+Len Mosunetuzumab SC Lenalidomide cycle 1 (Trial)||No mapping|\r\n|CO41942 Mosun+Len Mosunetuzumab SC Lenalidomide cycles 2-12 (Trial)||No mapping|\r\n|Denosumab (metastases) 12 weekly||No mapping|\r\n|Bortezomib (TTP)||No mapping|\r\n|Dexamethasone pre/post docetaxel 20mg IV 8mg po 3 day (RBFT)||No mapping|\r\n|CT7001-001 Module 2 part A (Trial)||No mapping|\r\n|Mesna for cyclophosphamide 750||No mapping|\r\n|ALL Phase 1 Induction (25-60 years)||No mapping|\r\n|Rituximab SC maintenance 2nd remission only (3 monthly) (Lymphoma)||No mapping|\r\n|UKALL 60+ Arm A Phase 1 and 2 induction (off study)||No mapping|\r\n|Trastuzumab SC (support)||No mapping|\r\n|EXCALIBER-RRMM (CC-220-MM-002) Arm A (Trial)||No mapping|\r\n|Aprepitant without dexamethasone (day 1 at home)||No mapping|\r\n|InterAACT Carboplatin Paclitaxel (CrCl) (off study)||No mapping|\r\n|Daratumumab Bortezomib Dexamethasone (neuropathy) (cycles 1 to 8 only) 21 rapid||No mapping|\r\n|Ondansetron temozolomide 5 day||No mapping|\r\n|KY1044-CT01 Atezolizumab KY1044 (Trial)||No mapping|\r\n|PETReA Rituximab SC Lenalidomide maintenance (Trial)||No mapping|\r\n|Mitotane (Lysodren)||No mapping|\r\n|Irinotecan Oxaliplatin Modified de Gramont (metastatic)||No mapping|\r\n|ALL Phase 2 Induction (25-60 years)||No mapping|\r\n|ACTICCA-1 Capecitabine (Trial)||No mapping|\r\n|Carboplatin AUC 10 (CrCl)||No mapping|\r\n|Carboplatin AUC 5 (CrCl)||No mapping|\r\n|Rituximab SC maintenance 1st remission only (2 monthly) (Lymphoma)||No mapping|\r\n|CA224048 Relatlimab Nivolumab BMS-986205 (Trial)||No mapping|\r\n|AC (sarcoma)||No mapping|\r\n|Ibrutinib (Waldenstroms macroglobulinaemia)||No mapping|\r\n|Midostaurin (mastocytosis)||No mapping|\r\n|COSI Mini Thiotepa Busulphan Fludarabine ATG (mini TBF) (Trial)||No mapping|\r\n|Capecitabine (1250) metastatic||No mapping|\r\n|Rituximab SC maintenance 1st remission only (2 monthly)||No mapping|\r\n|Ibrutinib (Mantle cell lymphoma)||No mapping|\r\n|Cisplatin Imatinib||No mapping|\r\n|ENRICH Rituximab SC maintenance (Trial)||No mapping|\r\n|Docetaxel (75) (metastatic) 21 day||No mapping|\r\n|SCOPE 2 Capecitabine Cisplatin cycles 2-4 Arms 2 and 4 (NCRN Trial)||No mapping|\r\n|1426-0001 Arm A BI 1387446 (Trial)||No mapping|\r\n|Mitomycin Modified de Gramont||No mapping|\r\n|Idarubicin IV (support)||No mapping|\r\n|RAMPART Arm B (Trial)||No mapping|\r\n|CTD (weekly cyclophosphamide)||No mapping|\r\n|AGI-134.FIM.101 Monotherapy treatment (Trial)||No mapping|\r\n|Panitumumab Oxaliplatin Modified DeGramont||No mapping|\r\n|Omeprazole 5 day||No mapping|\r\n|Carboplatin 21 day (CrCl)||No mapping|\r\n|GRN163LMYF3001  Arm A Imetelstat (Trial)||No mapping|\r\n|ENRICH Ibrutinib Rituximab SC maintenance (Trial)||No mapping|\r\n|NUTIDE 302 Arm 2A NUC-3373 weekly Oxaliplatin (Trial)||No mapping|\r\n|COPELIA Arm 2 Cediranib Paclitaxel (Trial)||No mapping|\r\n|Fludarabine Cyclophosphamide Rituximab CLL (Flu-Cy-R) (Oral)||No mapping|\r\n|Panitumumab Oxaliplatin Modified de Gramont||No mapping|\r\n|VTDPACE (cyclophosphamide bolus)||No mapping|\r\n|Dexamethasone pre/post docetaxel 8mg po 3 day||No mapping|\r\n|ENRICH Ibrutinib Rituximab SC maintenance (NCRN Trial)||No mapping|\r\n|Docetaxel Phesgo SC (metastatic)||No mapping|\r\n|FCiST Streptozocin Cisplatin Fluorouracil (Neuroendocrine) inpt||No mapping|\r\n|Cabozantinib (RCC) (MAP)||No mapping|\r\n|PARTNER AZD6738 Durvalumab (PARTNERING) (Trial)||No mapping|\r\n|ENRICH Rituximab SC maintenance (NCRN Trial)||No mapping|\r\n|Docetaxel Carboplatin Phesgo SC (neoadjuvant node positive) CrCl||No mapping|\r\n|Capecitabine (1250) (biliary tract)||No mapping|\r\n|Etoposide IV (HLH)||No mapping|\r\n|PARTNER FEC100 (Trial)||No mapping|\r\n|RAINBOW Dexamethasone Cyclophosphamide Rituximab (Trial)||No mapping|\r\n|COPELIA Arm 3 Olaparib Cediranib (Trial)||No mapping|\r\n|Imatinib (GIST/sarcomas)||No mapping|\r\n|AG946-C-002 Phase 2a (Trial)||No mapping|\r\n|Temozolomide 150/200 (astrocytoma)||No mapping|\r\n|UKALL 2011 Regimen B Induction standard dexamethasone (off study)||No mapping|\r\n|Obinutuzumab CVP||No mapping|\r\n|CO41942 Mosun+Len Mosunetuzumab Lenalidomide cycle 1 (Trial)||No mapping|\r\n|PCYC-1116-CA; Ibrutinib (commercial trial)||No mapping|\r\n|Ibrutinib (CLL)||No mapping|\r\n|Ibrutinib (Waldenstroms macroglobulinaemia)||No mapping|\r\n|Daratumumab SC Bortezomib Dexamethasone (cycles 1 to 8 only) (21 day)||No mapping|\r\n|Dexamethasone pre/post docetaxel 4mg po 3 day||No mapping|\r\n|Cyclophosphamide Fludarabine TBI FIC (MUD transplant/cord cells)||No mapping|\r\n|NUTIDE 302 Arm 2B NUC-3373 weekly Irinotecan (Trial)||No mapping|\r\n|Daratumumab SC Bortezomib Dexamethasone (cycle 9 onwards) (28 day)||No mapping|\r\n|Constellation (0610-02) Arm 1 CPI-0610 monotherapy (Trial)||No mapping|\r\n|Trastuzumab Oxaliplatin Modified de Gramont||No mapping|\r\n|EC Capecitabine Daypt||No mapping|\r\n|M14-239 Telisotuzumab vedotin (Trial)||No mapping|\r\n|BI 1280.8 Arm A BI 836845 (1000mg) Enzalutamide (Trial)||No mapping|\r\n|Irinotecan Modified DeGramont||No mapping|\r\n|UKALL 2011 Regimen B Delayed intensification (off study)||No mapping|\r\n|CABL001A2001B Asciminib Imatinib arm (Trial)||No mapping|\r\n|Daratumumab Bortezomib Dexamethasone (cycles 1 to 8 only) (21 day) rapid rate||No mapping|\r\n|Bortezomib weekly Cyclophosphamide Dexamethasone (CyBorDex) (Amyloidosis)||No mapping|\r\n|COSI Fludarabine Busulphan 4 (FB4) (Trial)||No mapping|\r\n|Imatinib (sarcoma)||No mapping|\r\n|CAR-T Fludarabine Cyclophosphamide Tisagenlecleucel (NHL)||No mapping|\r\n|POD1UM-303 (InterAACT 2) INCMGA00012 / placebo Paclitaxel Carboplatin (Trial)||No mapping|\r\n|PLATO Mitomycin Capecitabine 28 days (ACT4 or ACT5) (NCRN Trial)||No mapping|\r\n|Capecitabine (1000) breast||No mapping|\r\n|R-CHOP-21 bolus||No mapping|\r\n|PRIMUS 001 Paclitaxel albumin bound Gemcitabine (Trial)||No mapping|\r\n|Chlorambucil-R (continuous)||No mapping|\r\n|Chlorambucil-R (days 1 to 14)||No mapping|\r\n|Methotrexate (50)||No mapping|\r\n|Imatinib (CML)||No mapping|\r\n|CABL001E2201 Asciminib 60mg Imatinib arm (Trial)||No mapping|\r\n|Docetaxel Carboplatin Pertuzumab Trastuzumab IV (adjuvant use only)||No mapping|\r\n|Oxaliplatin Capecitabine 21 day||No mapping|\r\n|ATOMIC-MESO (POLARIS 2015-003) ADI-PEG/Placebo Cisplatin Pemetrexed (Trial)||No mapping|\r\n|Gemtuzumab Daunorubicin Cytarabine induction||No mapping|\r\n|Cyclophosphamide TBI Alemtuzumab (MUD transplant)||No mapping|\r\n|Vyxeos (Daunorubicin / Cytarabine) liposomal consolidation||No mapping|\r\n|CABL001A2301 ABL001 arm (Trial)||No mapping|\r\n|SCOPE 2 Carboplatin (CrCl) Paclitaxel cycles 2-4 Arms 1 and 3 (NCRN Trial)||No mapping|\r\n|UTX-TGR-205 Arm A Ublituximab TGR-1202 (Trial)||No mapping|\r\n|ENRICH Bendamustine-R (Trial)||No mapping|\r\n|Carmustine Thiotepa (High dose)||No mapping|\r\n|CNIS793B12201 Arm 2 NIS793 Gemcitabine Nab-Paclitaxel (Trial)||No mapping|\r\n|Enzalutamide (newly diagnosed metastatic)||No mapping|\r\n|Cetuximab 2 weekly||No mapping|\r\n|Cisplatin (support)||No mapping|\r\n|CNIS793B12201 Arm 1 Spartalizumab NIS793 Gemcitabine Nab-Paclitaxel (Trial)||No mapping|\r\n|SCOPE 2 Carboplatin (CrCl) Paclitaxel cycle 1 All patients (Trial)||No mapping|\r\n|MoTD Fludarabine Melphalan experimental group 3 (Trial)||No mapping|\r\n|MAGNETISMM-5 (C1071005) Arm C Daratumumab Pomalidomide Dexamethasone (Trial)||No mapping|\r\n|Paclitaxel Carboplatin 21 day (CrCl)||No mapping|\r\n|Dexamethasone pre/post docetaxel 20mg IV 8mg po 2 day||No mapping|\r\n|Dexamethasone pre/post docetaxel 20mg IV 8mg po 3 day||No mapping|\r\n|ICON 9 Olaparib Cediranib Arm 1 (Trial)||No mapping|\r\n|Sunitinib (GIST)||No mapping|\r\n|FLAIR Ibrutinib Venetoclax (NCRN Trial)||No mapping|\r\n|Abiraterone Prednisolone (support)||No mapping|\r\n|Oxaliplatin Modified de Gramont||No mapping|\r\n|Abiraterone Prednisolone (after at least 3 months of stable dose abiraterone)||No mapping|\r\n|COSI Fludarabine Busulphan 2 (FB2) (Trial)||No mapping|\r\n|daNIS-3 NIS793 Tislelizumab FOLFIRI Bevacizumab (Trial)||No mapping|\r\n|Epirubicin (20) weekly||No mapping|\r\n|SGN35-032 Brentuximab vedotin Cyclophosphamide Doxorubicin Prednisone (Trial)||No mapping|\r\n|IMGN632-0802 Regimen C AZA+VEN+IMGN632 (Trial)||No mapping|\r\n|Docetaxel (75) (NSCLC)||No mapping|\r\n|Oxaliplatin Modified DeGramont||No mapping|\r\n|SCOPE 2 Capecitabine Cisplatin cycle 1 All patients (NCRN Trial)||No mapping|\r\n|Omeprazole premed||No mapping|\r\n|5F9003 Hu5F9-G4 Rituximab (Trial)||No mapping|\r\n|Capecitabine (2000mg bd) 7/7||No mapping|\r\n|Midostaurin Daunorubicin Cytarabine (cytarabine bolus DA)||No mapping|\r\n|Gemcitabine Dexamethasone Cisplatin (GDP) (Daypatient)||No mapping|\r\n|Docetaxel Carboplatin Phesgo SC (neoadjuvant node negative / unknown) CrCl||No mapping|\r\n|FLAG Venetoclax||No mapping|\r\n|BEAM Alemtuzumab (Allograft)||No mapping|\r\n|CABL001E2201 Asciminib 40mg Imatinib arm (Trial)||No mapping|\r\n|CompARE Arm 5 Cisplatin Durvalumab (NCRN Trial)||No mapping|\r\n|Capecitabine (1000)||No mapping|\r\n|Olaparib capsules (400mg bd)||No mapping|\r\n|IMC-F106C-101 IMC-F106C Paclitaxel albumin bound (Trial)||No mapping|\r\n|Gemcitabine Dexamethasone Cisplatin (GDP)||No mapping|\r\n|ICE modified||No mapping|\r\n|CAR-T Fludarabine Cyclophosphamide Axicabtagene ciloleucel||No mapping|\r\n|EC Paclitaxel Carboplatin (CrCl)||No mapping|\r\n|Gemcitabine (1000) Carboplatin (CrCl) (breast)||No mapping|\r\n|Gemcitabine (pancreas)||No mapping|\r\n|5F9005 Hu5F9-G4 Azacitidine evaluation (Trial)||No mapping|\r\n|Cytarabine HD Rituximab||No mapping|\r\n|Mitotane||No mapping|\r\n|COSI Fludarabine Busulphan 2 (FB4) (off study)||No mapping|\r\n|Sunitinib (pNET)||No mapping|\r\n|OASIS II Arm B Ibrutinib Venetoclax Rituximab (Trial)||No mapping|\r\n|MoTD Fludarabine Busulfan MF experimental group 3 (Trial)||No mapping|\r\n|POMB/ACE||No mapping|\r\n|R-VP||No mapping|\r\n|Dasatinib (chronic phase CML)||No mapping|\r\n|Docetaxel Pertuzumab Trastuzumab IV (metastatic)||No mapping|\r\n|Paclitaxel albumin-bound Phesgo SC (metastatic)||No mapping|\r\n|Daunorubicin liposomal Cytarabine liposomal (Vyxeos) induction||No mapping|\r\n|IMC-F106C-101 IMC-F106C monotherapy (Trial)||No mapping|\r\n|Docetaxel Carboplatin Phesgo SC (adjuvant) CrCl||No mapping|\r\n|Capecitabine (1250)||No mapping|\r\n|Paclitaxel weekly Carboplatin weekly (CrCl)||No mapping|\r\n|Bevacizumab Paclitaxel Carboplatin 21 day (CrCl) (ovarian/fallopian/peritoneal)||No mapping|\r\n|Isatuximab Pomalidomide Dexamethasone (EAMS)||No mapping|\r\n|Docetaxel Carboplatin Pertuzumab Trastuzumab IV(neoadjuvant node neg/unknown)Cr||No mapping|\r\n|Vyxeos (Daunorubicin / Cytarabine) liposomal induction||No mapping|\r\n|Paclitaxel Carboplatin EC (CrCl)||No mapping|\r\n|Brentuximab vedotin Cyclophosphamide Doxorubicin Prednisolone (Bv-CHP)||No mapping|\r\n|Thiotepa Fludarabine Treosulfan (Cord transplant)||No mapping|\r\n|Chlorambucil-R (days 1 to 7)||No mapping|\r\n|Ipilimumab Nivolumab (mesothelioma) (EAMS)||No mapping|\r\n|Darolutamide Docetaxel Prednisolone (ORBIS)||No mapping|\r\n|P+R-ICE Arm B Pembrolizumab R-ICE (Trial)||No mapping|\r\n|Cemiplimab (support)||No mapping|\r\n|ECF Daypt||No mapping|\r\n|Gemcitabine (1200) Carboplatin (CrCl) (NSCLC/SCLC)||No mapping|\r\n|Bendamustine-R Polatuzumab (not BMT candidate)||No mapping|\r\n|EC Docetaxel Phesgo SC (adjuvant)||No mapping|\r\n|ENRICH Bendamustine-R (NCRN Trial)||No mapping|\r\n|Temozolomide (brain) (support)||No mapping|\r\n|Daunorubicin liposomal Cytarabine liposomal (Vyxeos) consolidation||No mapping|\r\n|Doxorubicin Dexrazoxane||No mapping|\r\n|GO42661 Atezolizumab Bevacizumab/placebo Gemcitabine Cisplatin (Trial)||No mapping|\r\n|Doxorubicin (sarcoma)||No mapping|\r\n|daNIS-3 NIS793 Tislelizumab mFOLFOX Bevacizumab (Trial)||No mapping|\r\n|ONC001 2 weekly IV monotherapy (Trial)||No mapping|\r\n|Carboplatin Etoposide (oral etoposide days 2 and 3) (CrCl)||No mapping|\r\n|Cyclophosphamide Fludarabine Thiotepa TBI RIC (Cord transplant)||No mapping|\r\n|Gemcitabine (1200) Carboplatin (CrCl)||No mapping|\r\n|Goserelin||No mapping|\r\n|Pembrolizumab Paclitaxel Carboplatin EC (neoadjuvant then adjuvant) (EDTA)||No mapping|\r\n|VTDPACE||No mapping|\r\n|Carboplatin Etoposide (CrCl)||No mapping|\r\n|Oxaliplatin Capecitabine (CapOx)||No mapping|\r\n|Gemcitabine (1000) Cisplatin (70 split)||No mapping|\r\n|Carboplatin (High grade glioma)||No mapping|\r\n|Gemcitabine (1000) Cisplatin (25) daypt||No mapping|\r\n|EC Docetaxel Pertuzumab Trastuzumab IV (neoadjuvant node positive)||No mapping|\r\n|Cisplatin (50) Etoposide (50) (NSCLC) Daypt||No mapping|\r\n|COSI Thiotepa Busulphan Fludarabine ATG (TBF) (Trial)||No mapping|\r\n|Bortezomib Cyclophosphamide daily Dexamethasone||No mapping|\r\n|Bortezomib daily Cyclophosphamide Dexamethasone (Amyloidosis)||No mapping|\r\n|Docetaxel Carboplatin Pertuzumab Trastuzumab (neoadjuvant)||No mapping|\r\n|Temozolomide (astrocytoma)||No mapping|\r\n|Lutetium-177 oxodotreotide (without support medication)||No mapping|\r\n|Carboplatin Etoposide (CrCl) (Oral etoposide days 2+3)||No mapping|\r\n|SCALOP-2 Gemcitabine Paclitaxel albumin bound (NCRN Trial)||No mapping|\r\n|Darolutamide (non-metastatic) (support)||No mapping|\r\n|Pembrolizumab Paclitaxel Carboplatin EC (neoadjuvant then adjuvant)||No mapping|\r\n|Daratumumab SC Lenalidomide Dexamethasone||No mapping|\r\n|Anti-thymocyte globulin (ATG) equine (aplastic anaemia)||No mapping|\r\n|Gemcitabine (1000) Carboplatin (CrCl) (ovarian)||No mapping|\r\n|Abiraterone Prednisolone||No mapping|\r\n|Liposomal doxorubicin (sarcoma)||No mapping|\r\n|Pembrolizumab Paclitaxel Carboplatin EC (neoadjuvant then adjuvant) (CrCl)||No mapping|\r\n|Paclitaxel weekly Pertuzumab Trastuzumab IV (adjuvant use only)||No mapping|\r\n|Cabozantinib (RCC)||No mapping|\r\n|Pertuzumab (neoadjuvant)||No mapping|\r\n|Cabozantinib (compassionate use)||No mapping|\r\n|Cisplatin Dexamethasone Gemcitabine PEG-Asparaginase (DDGP)||No mapping|\r\n|ASTX727-02 ASTX727 then Decitabine (Trial)||No mapping|\r\n|Cabazitaxel||No mapping|\r\n|EC Docetaxel Pertuzumab Trastuzumab IV (neoadjuvant node negative / unknown)||No mapping|\r\n|Paclitaxel Ifosfamide Cisplatin (TIP)||No mapping|\r\n|Gemtuzumab Daunorubicin Cytarabine consolidation||No mapping|\r\n|BGB-3111-LTE1 Zanubrutinib (Trial)||No mapping|\r\n|Cyclophosphamide Etoposide Procarbazine Prednisolone maintenance (PEP-C)||No mapping|\r\n|Carfilzomib Lenalidomide Dexamethasone (CarLenDex)||No mapping|\r\n|Palbociclib||No mapping|\r\n|Carboplatin Fluorouracil (CrCl) (H&N) daypt||No mapping|\r\n|Neratinib||No mapping|\r\n|Bevacizumab (7.5mg/kg) Paclitaxel Carboplatin (CrCl) (ovarian)||No mapping|\r\n|Thiotepa Busulfan Fludarabine ATG (Allograft)||No mapping|\r\n|Topotecan (oral)||No mapping|\r\n|Fludarabine TBI post transplant Cyclophosphamide MUD||No mapping|\r\n|Cyclophosphamide Dexamethasone Rituximab (DRC)||No mapping|\r\n|Sorafenib||No mapping|\r\n|Bortezomib weekly Cyclophosphamide Dexamethasone||No mapping|\r\n|EC Docetaxel Pertuzumab Trastuzumab (neoadjuvant node positive)||No mapping|\r\n|Paclitaxel weekly Phesgo SC (adjuvant use only)||No mapping|\r\n|Daratumumab SC Bortezomib Thalidomide Dexamethasone||No mapping|\r\n|Bortezomib||No mapping|\r\n|Gemcitabine (1000) Carboplatin (CrCl)||No mapping|\r\n|TOPAZ-1 Gemcitabine Cisplatin Durvalumab / placebo (Trial)||No mapping|\r\n|Ifosfamide Etoposide (5 day)||No mapping|\r\n|Bevacizumab (15mg/kg) Paclitaxel Carboplatin (CrCl) (ovarian)||No mapping|\r\n|Darolutamide Docetaxel Prednisolone||No mapping|\r\n|Carboplatin Paclitaxel Trastuzumab (GOJ) (CrCl)||No mapping|\r\n|Cisplatin (75) Etoposide (100) (Neuroendocrine) daypt||No mapping|\r\n|VIP Cisplatin Etoposide Ifosfamide||No mapping|\r\n|Gemcitabine (1000) Cisplatin (70) daypt||No mapping|\r\n|Daratumumab SC||No mapping|\r\n|Docetaxel Carboplatin Pertuzumab Trastuzumab (neoadjuvant node positive) CrCl||No mapping|\r\n|Gemcitabine (1000) Cisplatin (70)||No mapping|\r\n|Cyclophosphamide Etoposide Procarbazine Prednisolone induction (PEP-C)||No mapping|\r\n|Paclitaxel weekly Phesgo SC (following completion of EC cycles)||No mapping|\r\n|Fludarabine Cyclophosphamide Alemtuzumab (Aplastic Anemia) (Allograft)||No mapping|\r\n|Trabectedin (sarcoma)||No mapping|\r\n|Midostaurin Daunorubicin Cytarabine||No mapping|\r\n|Olaparib TABLETS (300mg bd)||No mapping|\r\n|Docetaxel Fluorouracil Oxaliplatin (FLOT)||No mapping|\r\n|Temozolomide 150/200||No mapping|\r\n|Gemcitabine (1000) Cisplatin (25)||No mapping|\r\n|Ribociclib||No mapping|\r\n|Nivolumab Vinorelbine (oral) Carboplatin (neoadjuvant) (CrCl)||No mapping|\r\n|Docetaxel Carboplatin Pertuzumab Trastuzumab IV (neoadjuvant node positive)CrCl||No mapping|\r\n|Daratumumab SC Pomalidomide Dexamethasone||No mapping|\r\n|Darolutamide (non-metastatic)||No mapping|\r\n|Docetaxel Carboplatin Pertuzumab Trastuzumab (neoadjuvant node neg/unknown)CrCl||No mapping|\r\n|Trabectedin||No mapping|\r\n|Gemcitabine (lymphoma)||No mapping|\r\n|Lenvatinib (Thyroid)||No mapping|\r\n|Olaparib (adjuvant)||No mapping|\r\n|Liposomal doxorubicin (support)||No mapping|\r\n|Streptozocin Capecitabine||No mapping|\r\n|EC Docetaxel Pertuzumab Trastuzumab (neoadjuvant node negative / unknown)||No mapping|\r\n|UKALL 60+ Arm B Intensification (off study)||No mapping|\r\n|Aprepitant oral||No mapping|\r\n|MATRIX NLMT Arm C (Palbociclib) (Trial)||No mapping|\r\n|Momelotinib (Compassionate Use)||No mapping|\r\n|Trastuzumab SC 21 day (support)||No mapping|\r\n|EP||No mapping|\r\n|LUD2015-005 Cohort D2 (NCRN Trial)||No mapping|\r\n|CT7001-001 Module 4 Cycle 1 onwards (Trial)||No mapping|\r\n|Atezolizumab 28 day (relapsed/metastatic)||No mapping|\r\n|Constellation (0610-02) Arm 3 CPI-0610 125mg + Rux R(-1) (Trial)||No mapping|\r\n|Cisplatin hydration (cisplatin dose 41-60mg/m2)||No mapping|\r\n|NUTIDE 302 Cohort 1c NUC-3373 + LV (Trial)||No mapping|\r\n|ALKS 4230-006 ARTISTRY-6 cohort 2 (Trial)||No mapping|\r\n|OCTOVA Arm B (NCRN Trial)||No mapping|\r\n|UKALL 60+ Arm B and D Maintenance (off study)||No mapping|\r\n|PLATFORM Arm A3 MEDI4736 maintenance (NCRN Trial)||No mapping|\r\n|Cisplatin weekly (ovarian) daypt||No mapping|\r\n|RXC004/0001 (Trial)||No mapping|\r\n|Aprepitant Dexamethasone (day 1 on ward)||No mapping|\r\n|CXD101-0901; CXD101 expansion (early phase trial)||No mapping|\r\n|Samuraciclib (compassionate use)||No mapping|\r\n|D933LC00001 (BEGONIA) Arm 7 (Trial)||No mapping|\r\n|MITHRIDATE (RG_16-148) Hydroxycarbamide (Trial)||No mapping|\r\n|EDP daypatient||No mapping|\r\n|ADCT-301-201 (Trial)||No mapping|\r\n|NUTIDE 701 weekly (Trial)||No mapping|\r\n|CompARE Arm 1 Cisplatin 40mg/m2 (NCRN Trial)||No mapping|\r\n|WO41554 (Trial)||No mapping|\r\n|PETRA (D9720C00001) Module 1 (Trial)||No mapping|\r\n|Mifamurtide (support)||No mapping|\r\n|RP3-301 RP3 monotherapy cohorts 3 and 4 (Trial)||No mapping|\r\n|2102-HEM-101 FT-2102 twice daily (Trial)||No mapping|\r\n|ACE-536-MDS-001 (MEDALIST) (NCRN Trial)||No mapping|\r\n|UKALL 14 Imatinib (NCRN Trial)||No mapping|\r\n|RP3-301 RP3 Nivolumab (Trial)||No mapping|\r\n|Nivolumab 28 day (relapsed/metastatic)||No mapping|\r\n|UKALL 2011 Regimen B Standard interim maintenance (off study)||No mapping|\r\n|ADVANCE Group 2 (Trial)||No mapping|\r\n|LOXO-BTK-18001 (Trial)||No mapping|\r\n|Sodium choride 0.9% 1000ml IV infusion over 60 minutes||No mapping|\r\n|ONC001 Part B (Trial)||No mapping|\r\n|Cetuximab / Panitumumab skin toxicity||No mapping|\r\n|AMMO Arm A ASTX727 (Trial)||No mapping|\r\n|ALKS 4230-006 ARTISTRY-6 cohort 1 (Trial)||No mapping|\r\n|RS-TS-101-01 (Trial)||No mapping|\r\n|Dapsone||No mapping|\r\n|Paracetamol IV||No mapping|\r\n|CHARIOT M6620 Tuesday doses (Trial)||No mapping|\r\n|NUTIDE 301 part 1 (NUC-3373 weekly) (NCRN Trial)||No mapping|\r\n|RADAR (Myeloma XV) RCyBorIsaD (Trial)||No mapping|\r\n|Rituximab IV 100mg (ITP)||No mapping|\r\n|Cardamon consolidation (CarCyDex) (NCRN Trial)||No mapping|\r\n|IMG-7289-CTP-201 IMG-7289 (Trial)||No mapping|\r\n|IMP-MEL IMM60 Pembrolizumab (Trial)||No mapping|\r\n|Venetoclax doses for delay in titration (add in on date of delay) (support)||No mapping|\r\n|DREAMM-9 Belantamab mafodontin Rd maintenance (Trial)||No mapping|\r\n|BGB-3111-302 BGB-3111 (NCRN Trial)||No mapping|\r\n|Mouth and Bowel Support Minus Metoclopramide||No mapping|\r\n|DREAMM-9 Belantamab mafodontin VRd (Trial)||No mapping|\r\n|CHARIOT M6620 Friday doses (Trial)||No mapping|\r\n|Ipi-Glio Arm B (Trial)||No mapping|\r\n|Aprepitant already has antiemetic dexamethasone prescribed (day 1 on ward)||No mapping|\r\n|Cisplatin hydration daypatient||No mapping|\r\n|Hydroxycarbamide (3 months)||No mapping|\r\n|RXC004/0001 Module 2 (Trial)||No mapping|\r\n|ASTX660-01 (7 days on/7 days off) (Trial)||No mapping|\r\n|Lansoprazole 5 day||No mapping|\r\n|UCL/17/0629 (PROMPT) Pembrolizumab (Trial)||No mapping|\r\n|Aprepitant already has antiemetic dexamethasone prescribed (day 1 at home)||No mapping|\r\n|BP42675 RO7122290 Cibisatamab part 1 (Trial)||No mapping|\r\n|GCSF lenograstim||No mapping|\r\n|MidAC||No mapping|\r\n|GS-US-352-4365 (Trial)||No mapping|\r\n|MIV-818-101/201 (Trial)||No mapping|\r\n|DS3201-A-U202 (Valentine) (Trial)||No mapping|\r\n|SCIB1-002 Pembrolizumab SCIB1 (Trial)||No mapping|\r\n|NG-350A-02 (FORTIFY) NG-350A Pembrolizumab (Trial)||No mapping|\r\n|LOXO-BTK-20019 Arm A LOXO-305 (Trial)||No mapping|\r\n|MOTION Vismeltinib / placebo (Trial)||No mapping|\r\n\r\n"
    }
  ]
}